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VI. Abstract 
Methicillin-resistant Staphylococcus aureus (MRSA) is a major cause of healthcare-associated infections 
including bacteraemia. Vancomycin has traditionally been the antibiotic of choice for treatment, but despite 
using the minimum inhibitory concentration (MIC) to guide treatment management, some patients still fail 
antibiotic therapy even when infected with strains that test as susceptible. This is further exacerbated with 
the emergence of vancomycin intermediate S. aureus (VISA) and heterogeneous vancomycin intermediate 
S. aureus (hVISA) strains, which exhibit reduced susceptibility to vancomycin. When exposed to sub-lethal 
concentrations of vancomycin, these VISA and hVISA subtypes are believed to undergo cell wall 
metabolism changes which increases the thickness of their cell walls and this form of resistance has been 
associated with sustained bacteraemia and increased mortality. 
Antibiotic tolerance is a phenotypic trait where an organism is resistant to the lethal killing of an antibiotic 
despite being inhibited by normal concentrations, and may explain the poorer outcome seen in patients with 
sustained bacteraemia. In vitro this interaction between an antibiotic concentration and bacterial growth or 
killing can be measured by the MIC (antibiotic concentration required to inhibit bacterial growth) and the 
minimum bactericidal concentration (MBC; that antibiotic concentration required to kill the bacterium) 
respectively. Using these two measures, tolerance is defined when the ratio of an isolates measured MBC 
to MIC is >32 after 24 hrs of incubation. 
Despite guidelines for MBC testing being issued in 1999, there is ongoing variation in the methodology 
used among testing laboratories, and the disparity in reported tolerance rates among S. aureus strains has 
lead clinicians to question the utility of MBC testing. 
Although there is conflicting data on the clinical significance of vancomycin-tolerant staphylococci, 
evidence suggests that tolerance may be an independent risk factor for poorer outcome, and the close 
association with hVISA and VISA strains may provide an understanding of the mechanisms that drive 
vancomycin resistance. 
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This study investigated whether variations in the methodology used in MBC and time-kill tests impacted 
the ability to detect antibiotic tolerance. This was achieved determining the effect of using different media 
and test conditions on tolerance rates seen in a collection of hVISA and VISA isolates from an ST239 
dominant MRSA population. 
The results from this study demonstrate that MBC results vary between tests and that the detection of 
antibiotic tolerance is highly dependent on testing conditions. Time-kill assays are the recommended 
method for detecting tolerance, and if MBC testing were to be performed, then it should be performed after 
isolates have undergone an in vitro vancomycin pre-exposure step.  
To better understand antibiotic tolerance and the mechanisms that drive vancomycin reduced susceptibility, 
MBC testing must be better standardised, and furthermore, the findings from this thesis propose an 
enhancement to current testing methodology which can be used in future large-scale studies to determine 
the clinical relevance of antibiotic tolerance. 
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Chapter 1 
Introduction 
 
1.1 Background 
S. aureus is a gram-positive bacterium which is found as part of the normal microorganism flora of human 
skin, and is generally non-pathogenic in healthy individuals. However, S. aureus is an opportunistic 
pathogen which can infect both immunocompromised and immuno-competent people, and has the ability 
to produce a variety of toxins and virulence factors in addition to having the ability to become resistant to 
antimicrobial agents (Chambers and Deleo 2009).  
S. aureus is recognised as a pathogen of great concern, as strains are often associated with various virulence 
factors and multi-drug resistance (Reis, Eisencraft et al. 1995, Kullar, Davis et al. 2011). S. aureus readily 
evolves resistance by utilising a number of mechanisms against multiple antibiotic types, and excessive 
antibiotic use has led to a high number of multi-resistant strains (Harris, Foster et al. 2002). For example, 
penicillin was introduced in the early 1940s for treating S. aureus infections, however resistance to 
penicillin resulting from the penicillinase enzyme encoded by the blaZ gene was seen as early as 1942 
(Lowy 2003). Methicillin was introduced in the United Kingdom in 1957 as an alternative for treating 
penicillin-resistant S. aureus infections, and resistance was seen within a few years of use. These 
methicillin-resistant S. aureus (MRSA) strains harbour the mecA gene, which is responsible for the 
synthesis of penicillin-binding-protein 2a (PBP2a). These proteins have a low affinity to β-lactam 
antibiotics, and these MRSA strains can still synthesize their cell wall even in the presence of methicillin 
(Hiramatsu 1995). Vancomycin, a glycopeptide antibiotic often used as a last resort for treatment, is now 
widely used to treat bacteraemia caused by MRSA strains, and as a consequence, reduced susceptibility and 
resistance to vancomycin have been reported (Hiramatsu, Hanaki et al. 1997, Chang, Sievert et al. 2003). 
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1.2 S. aureus bacteraemia 
 1.2.1 Risk factors 
S. aureus is a major cause of bacteraemia; in Australia, 6,900 episodes of S. aureus bacteraemia occur 
annually, with 24% of these cases being caused by MRSA strains (Turnidge, Nimmo et al. 2007). These 
MRSA infections are strongly associated with sustained bacteraemia (bacteraemia lasting from 3 up to 7 
days from onset), higher hospital costs, a longer duration of stay, and higher mortality and morbidity 
(Lodise and McKinnon 2005, Moise, Sakoulas et al. 2007, Kullar, Davis et al. 2011, Pasticci, Moretti et al. 
2011, Hope, Blackburn et al. 2013). Sustained bacteraemia is a common manifestation of bloodstream 
infections caused by S. aureus (van Hal, Jensen et al. 2012), and while admission to ICU and the presence 
of a central venous catheter or other foreign bodies such as a pacemaker or prosthetic joint are recognized 
as risk factors (Hawkins, Huang et al. 2007, Honda, Doern et al. 2011), infection with hVISA/VISA isolates 
has been more closely associated with sustained bacteraemia (Howden, Johnson et al. 2006, Rybak, 
Leonard et al. 2008).  Sustained bacteraemia is associated with an enhanced risk of additional complications 
such as infective endocarditis, and poorer outcomes and higher mortality rates have been seen in these 
patients compared to patients with non-sustained infections (Hawkins, Huang et al. 2007, Yoon, Kim et al. 
2010).  
 1.2.2 Endocarditis 
As a result of high bacterial loads, sustained bacteraemia substantially increases the risk of developing 
infective endocarditis (Holland, Arnold et al. 2014); loads which are similar to what is seen in hVISA 
bloodstream infections (Charles, Ward et al. 2004, Howden 2005). Cases of MRSA endocarditis are 
invariably bacteraemic, and poorer patient outcomes are seen in patients with MRSA endocarditis and is 
associated with a fatal outcome if improperly treated (Kullar, Davis et al. 2011, Pasticci, Moretti et al. 2011, 
Holland, Arnold et al. 2014).  
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1.2.3 Genetic markers for sustained bacteraemia 
There are no genetic markers in S. aureus which can predict a sustained bacteraemia infection or treatment 
failure. Studies have suggested the accessory gene regulator (agr) locus of S. aureus, which acts as a global 
virulence regulator, as an important mechanism affecting vancomycin susceptibility (Sakoulas, Eliopoulos 
et al. 2003, Moise-Broder, Sakoulas et al. 2004, Sakoulas, Moise-Broder et al. 2004, Verdier, Reverdy et 
al. 2004, Rose, Fallon et al. 2012), but the relevance of agr dysfunction in cases of sustained bacteraemia 
is still unclear (Kullar, Davis et al. 2011, Seidl, Chen et al. 2011). Even S. aureus strains that possess the 
highly potent toxin generated from the Panton-Valentine leukocidin (PVL) gene has not been associated 
with sustained bacteraemia nor endocarditis (Holmes, Ganner et al. 2005, Kullar, Davis et al. 2011).  
1.2.4 Relevance of vancomycin therapy 
Vancomycin is a glycopeptide antimicrobial and is the most widely used agent as therapy for serious 
infections caused by gram-positive organisms (Jones 2006). Vancomycin derives from the organism 
Streptomyces orientalis, and acts by inhibiting the bio-synthesis of peptidoglycan (bacterial cell wall) and 
the assembly of N-acetylglucosamine and N-acetylmuramic acid (NAM-NAG) polypeptide into the 
growing peptidoglycan chain. It inhibits peptidoglycan bio-synthesis by reacting with D-Ala-D-Ala, 
blocking the release of terminal D-Ala and intra-bond formation, resulting in cell death (Chakraborty, Sahu 
et al. 2010). Vancomycin was initially used to treat infections with penicillin-resistant Staphylococcus 
aureus before alternative, less-toxic drugs were introduced. However with the onset of antimicrobial 
resistance, highlighted by increasing reports and hospital outbreaks of methicillin resistance in S. aureus 
strains in the 1960s, there was a greater dependency on vancomycin for treating these infections. While 
vancomycin was initially used as a last resort for treatment, it is now widely used as a first line therapy to 
treat MRSA bacteraemia (Rose, Fallon et al. 2012). 
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Figure 1.1 Chemical structure of vancomycin. Image sourced from Jones (Jones 2006). 
 
Resistance to vancomycin remains rare, however there are increasing numbers of reported cases of MRSA 
strains which exhibit reduced susceptibility to vancomycin (van Hal, Jensen et al. 2012). These VISA and 
hVISA strains are associated with sustained bacteraemia, resulting from reduced efficacy seen with 
vancomycin when used to treat MRSA bacteraemia (van Hal, Jensen et al. 2012). 
 
1.3 S. aureus strains with reduced vancomycin susceptibility 
The CLSI define VISA as an S. aureus strain with a vancomycin MIC of 4-8 µg/mL (CLSI 2007), and 
hVISA are S. aureus strains that normally test within the vancomycin susceptible range (MIC <2 µg/mL), 
but a sub-population of organisms show intermediate resistance to vancomycin (Cosgrove, Carroll et al. 
2004). The mechanism in which decreased susceptibility occurs in these strains is still not yet fully 
understood (Aeschlimann, Hershberger et al. 1999), though it is believed that these hVISA and VISA 
strains develop a thickened peptidoglycan cell wall (to which a greater number of vancomycin molecules 
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bind to moieties within the cell wall rather than at the active site), and consequently higher concentrations 
of the antibiotic are required in order to kill the bacteria (Hanaki, Labischinski et al. 1998). The production 
of these thickened cell walls is associated with increased production of cell wall precursors, decreased 
autolysis, increased penicillin-binding proteins and a slower growth rate (Aeschlimann, Hershberger et al. 
1999, Joyce and Woods 2004). This contrasts the mechanism of resistance seen in vancomycin-resistant S. 
aureus (VRSA) strains, which acquire resistance by conjugal transfer of the vanA gene from vancomycin-
resistant enterococci. Furthermore, VRSA infections are rarely associated with bloodstream infections 
(Gould 2010, van Hal, Jensen et al. 2012, Gould 2013). 
1.3.1 Genetic correlates 
The genetic resistance mechanism of VISA/hVISA isolates is still not completely understood due to the 
complex metabolic adaptation possessed by these strains, and the vanA and vanB genes that are responsible 
for vancomycin resistance in enterococci and vancomycin resistant S. aureus have not been associated with 
these isolates (Joyce and Woods 2004, Verdier, Reverdy et al. 2004, Jones 2006). Therefore routine clinical 
laboratories rely on phenotypic methods to detect these VISA/hVISA strains (van Hal and Paterson 2011). 
1.3.2 Detection issues 
A modified population-analysis profile is considered the gold standard for detecting VISA/hVISA strains 
(Wootton, Howe et al. 2001). However this method is labour-intensive and unachievable in a clinical 
laboratory setting (van Hal, Wehrhahn et al. 2011), and therefore laboratories rely on MIC testing 
recommended by the CLSI in order to detect these strains (CLSI 2012). Automated broth-based 
microdilution methods such as Microscan (Siemens AG, Erlangen, Germany), Phoenix (Becton-Dickinson, 
Franklin Lakes, USA) and Vitek (bioMerieux, Craponne, France), in addition to disc diffusion methods fail 
to detect VISA and hVISA strains and are no longer recommended as testing methods (Cosgrove, Carroll 
et al. 2004, Moise, Sakoulas et al. 2007, Rybak, Vidaillac et al. 2013). The CLSI recommend broth 
microdilution MIC testing for determining vancomycin susceptibility in S. aureus, however routine clinical 
laboratories use the Etest (bioMerieux, Craponne, France) method due to its ease of use (Lodise, Graves et 
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al. 2008, Holmes, Turnidge et al. 2011, Kullar, Davis et al. 2011, Pasticci, Moretti et al. 2011). While the 
CLSI recommend Etest as an acceptable alternative testing method, the sensitivity in detecting hVISA 
strains in broth microdilution and Etest methods is poor (van Hal, Wehrhahn et al. 2011). Laboratories have 
explored modifications to the Etest method such as the macromethod Etest or glycopeptide resistance 
detection Etest tests, though these methods still fail to reliably detect hVISA strains (van Hal, Wehrhahn et 
al. 2011). Overall, the detection issues associated with MIC testing creates additional challenges in the 
management of patients with S. aureus bloodstream infections, as infections with VISA/hVISA strains may 
be under reported and inappropriate therapy may be administered as a consequence (Sader, Jones et al. 
2009). 
 
1.4 Staphylococcus aureus minimum inhibitory concentration testing 
 1.4.1 Principle 
Broth and/or agar dilution methods are used to quantitatively measure the in vitro activity of vancomycin 
against S. aureus (CLSI 2012). A series of tubes or plates are prepared to which various concentrations of 
vancomycin is added. The tubes or plates are inoculated with a standardised suspension of S. aureus, and 
after incubation at 35 + 2ºC, the tests are examined and the MIC is determined. With the Etest method, a 
plastic strip containing increasing concentrations of vancomycin is placed on a Mueller-Hinton agar plate 
that is pre-inoculated with a suspension equivalent to a 0.5 McFarland standard. The MIC is the lowest 
concentration of antibiotic needed to inhibit bacterial growth, though this does not imply that the organism 
is necessarily killed (Finberg, Moellering et al. 2004, Joyce and Woods 2004, CLSI 2012). Vancomycin 
MIC interpretive criteria for S. aureus is listed in Table 1.1.  
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Table 1.1 CLSI guidelines for determining vancomycin susceptibility in S. aureus (CLSI 2007) 
Organism Antimicrobial 
agent 
MIC interpretive criteria 
(µg/mL)1 
Comments 
S I R 
S. aureus Vancomycin <2 4-8 >16 MIC tests should be performed to 
determine the susceptibility of all 
isolates of staphylococci to 
vancomycin.  The disc test does not 
differentiate vancomycin-
susceptible isolates of S. aureus 
from vancomycin-intermediate 
isolates. 
Disc diffusion testing is not reliable 
for testing vancomycin 
1MIC, (minimum inhibitory concentration); S, (susceptible); I, (intermediate); R, (resistant) 
 
1.4.2 Differences in methodology 
Broth microdilution is considered the gold standard for susceptibility testing and is the method used by the 
CLSI when establishing vancomycin MIC breakpoints. Due to the ease of use however, Etest is the method 
of choice for routine clinical diagnostic laboratories when determining vancomycin MICs (Kullar, Davis et 
al. 2011, Pasticci, Moretti et al. 2011, Rose, Fallon et al. 2012); favoured over the broth microdilution 
method which is considered too laborious and inconvenient (Moise, Sakoulas et al. 2007, Kullar, Davis et 
al. 2011, Pasticci, Moretti et al. 2011, Rose, Fallon et al. 2012, Sancak 2014).  
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Poor correlation and a high degree of variability is seen in the Etest method (Sancak 2014), and MICs 
obtained via Etest are consistently higher when compared to the broth microdilution method (Sakoulas, 
Moise-Broder et al. 2004, Holmes, Turnidge et al. 2011, Kullar, Davis et al. 2011, Rose, Fallon et al. 2012).  
 1.4.3 Vancomycin susceptibility and relationship with therapy 
While hVISA and VISA strains are closely associated with high mortality and sustained bacteraemia 
(Sakoulas, Moise-Broder et al. 2004, Moise, Sakoulas et al. 2007, Lodise, Graves et al. 2008, Holmes, 
Turnidge et al. 2011, Kullar, Davis et al. 2011), there are conflicting reports of treatment failure and 
increased mortality associated with vancomycin MICs near the cut-off for susceptibility (i.e. MIC of 1.5-2 
µg/mL) (Moise, Sakoulas et al. 2007, van Hal, Jensen et al. 2012, Murray, Zhao et al. 2013). Many studies 
that correlate increased-but-susceptible vancomycin MICs with poorer patient outcomes base their findings 
on the Etest method, and studies have attributed poorer outcomes seen in MRSA bacteraemia to a 
phenomenon known as ‘MIC creep’ (Hawkins, Huang et al. 2007, Dhand and Sakoulas 2012), where 
gradual increases in vancomycin MIC have been reported over time but are still below the breakpoint for 
susceptibility. However, as the Etest method is known to produce higher MICs compared to the broth 
microdilution method and is unable to detect small increments in the MIC in the clinical setting (Hawkins, 
Huang et al. 2007, Hope, Blackburn et al. 2013), this phenomenon has been heavily criticized (Jones 2006, 
Pasticci, Moretti et al. 2011, Reynolds, Hope et al. 2012). Furthermore, studies have refuted this trend of 
increasing vancomycin MICs over time, citing retrospective literature searches and testing of earlier 
isolates, which both demonstrate long-term presence of VISA, pre-dating even the first reported case in 
1997 (Hiramatsu, Hanaki et al. 1997, Rybak, Cha et al. 2005, Jones 2006). 
Varied treatment outcomes have been seen in patients with sustained bacteraemia caused by MRSA strains 
exhibiting a high-but-susceptible vancomycin MIC (Jung, Song et al. 2014). It has been argued whether the 
current vancomycin MIC susceptible breakpoint of <2 µg/mL should be lowered further (Moise, Sakoulas 
et al. 2007), or whether there may be additional organism or host factors, not solely the vancomycin MIC 
affecting the clinical response.  
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The efficacy of vancomycin has also been questioned, as this antibiotic has been referred to as having 
suboptimal activity (van Hal, Jensen et al. 2012), and treatment failure has been reported when insufficient 
concentrations of vancomycin are administered during therapy (Kullar, Davis et al. 2011, Gonzalez, 
Sevillano et al. 2013).  
In conclusion, there are no definitive correlates which can predict the treatment efficacy of vancomycin in 
patients infected with sustained bacteraemia caused by MRSA strains.  An alternative explanation,  in 
addition to understanding the reduced vancomycin susceptibility seen in VISA/hVISA strains, may depend 
on whether the organism possess an ability to evade the bactericidal killing of vancomycin; an in vitro 
phenomenon known as vancomycin tolerance (Jones 2006, Cazares-Dominguez, Cruz-Cordova et al. 
2015).  
 
1.5 Vancomycin tolerance 
Vancomycin tolerance is a novel form of resistance which improves the chance of bacterial survival; a 
phenotypic trait where bacterial growth is being inhibited and it continues to survive despite increasing 
antibiotic concentrations (Sabath, Wheeler et al. 1977, Handwerger and Tomasz 1985). This is in contrast 
to resistance where both growth and bacterial survival are not affected by standard antibiotic concentrations. 
In vitro, this interaction between an antibiotic concentration and bacterial growth or killing can be measured 
by the MIC (antibiotic concentration required to inhibit bacterial growth) and the MBC (antibiotic 
concentration required to kill the bacterium), respectively.  Using these two measures, tolerance is defined 
when the ratio of an isolates measured MBC to MIC is >32 after 24 h of incubation (May, Shannon et al. 
1998, CLSI 1999, Sader, Jones et al. 2009, Honda, Doern et al. 2011).  
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1.6 MBC 
 1.6.1 Introduction 
Vancomycin tolerance is determined by investigating bacterial survival that occurs beyond the point of an 
organism’s MIC; referred to as an MBC test. As such, MBC testing involves the transfer of any clear MIC 
wells onto solid media in order to determine cell viability, and similar to broth microdilution MIC testing, 
has high costs associated with the test and is too labour-intensive to be performed in routine clinical 
laboratories (Miyazaki, Takata et al. 2011).  
1.6.2 Factors that influence the MBC test 
The methodology for MBC testing is subject to many biological and technical factors, and, as such, the 
clinical significance is hard to determine (Taylor, Schoenknecht et al. 1983, Pelletier 1984, Washington 
1988). While the clinical relevance of biological factors is uncertain, technical factors are believed to 
contribute to the lack of correlation and varied results seen in MBC tests, raising criticisms toward the 
accuracy and significance of the test (Kaye 1980, Sherris 1986, May, Shannon et al. 1998, Pasticci, Moretti 
et al. 2011). In an attempt to address these factors and establish inter-laboratory reproducibility and 
reliability, the Clinical and Laboratory Standards Institute (CSLI) in 1999 issued recommendations for 
MBC testing (CLSI 1999) which was followed by methodology, essentially reflecting the CLSI guidelines, 
published by the American Society for Microbiology (ASM) (Garcia 2010).  
1.6.3 Biological factors 
1.6.3.1 Persister cells 
Persisters occur when a small number of bacterial cells survive the lethal killing of an antibiotic, but are 
just as susceptible as the parent strain and no greater proportion of persistence is seen upon repeat testing 
(Gunnison, Fraher et al. 1964). This is thought to occur as a result of slower-growing cells that are not 
killed by the antibiotic, and as the rate of killing is related to the rate of bacterial growth, the antibiotic will 
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have a reduced killing effect (Tuomanen, Cozens et al. 1986). Therefore, as growth of a microorganism 
reaches its maximum, its growth rate slows and so does the rate of bactericidal killing (CLSI 1999).  
1.6.3.2 Paradoxical effect 
The paradoxical effect is where the proportion of survivors increase with each increasing antibiotic 
concentration beyond the MBC. This phenomenon is common in S. aureus and for cell-wall active agents, 
where penicillin-binding inefficiencies prevent organism growth from the full bactericidal killing of an 
antibiotic (French 2006). The clinical relevance of the paradoxical effect is unclear and is ignored when 
seen in S. aureus (CLSI 1999). 
1.6.4 Technical factors 
1.6.4.1 Growth phase of inoculum 
The most common variation between MBC studies is the growth phase of bacteria used for testing. 
Stationary phase cultures (for example, cultures that are >8 h) will include a number of dormant cells which 
are not as susceptible and therefore cause diminished killing rates. Lag phase cultures and cultures that have 
undergone a change in test conditions such as change in temperature or inoculation from solid to liquid 
media, will also include less metabolically active cells, resulting in less killing endpoints. Several studies 
strongly recommend logarithmic phase growth for MBC testing, and the CLSI state this is achieved for 
staphylococci within 6 h (Goessens, Fontijne et al. 1982, Taylor, Schoenknecht et al. 1983, Sherris 1986, 
CLSI 1999). 
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Figure 1.2 Bacterial growth curve. Growth curve representing a typical bacterial culture. a: lag phase; b: 
logarithmic phase; c: stationary phase; d: death phase. Image sourced from CLSI (CLSI 1999). 
 
1.6.4.2 Size of inoculum 
Inoculum size is one of the most important variables that can affect MBC testing. Low concentrations of 
bacteria (e.g. 104 CFU/mL) are readily killed, and high concentrations of log-phase cultures (107-108 
CFU/mL) are killed more rapidly than those in stationary phase (CLSI 1999). Variations in inoculum 
density can also affect MIC endpoints, and therefore the CLSI recommend a final inoculum size of 5 x 105 
CFU/mL (CLSI 2012). 
Inocula from log phase culture should be prepared in a flask or beaker which is continuously agitated in a 
shaker incubator to ensure uniform growth. While the inoculum size can be estimated on the day of testing 
against a known McFarland reference standard, the final inoculum size of approximately 5 x 105 CFU/mL 
should be confirmed by colony count for interpretation of killing endpoints the following day (CLSI 1999).  
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1.6.4.3 Insufficient contact 
During testing, organisms may adhere to the microtitre well (or test tube) above the meniscus, leading to 
insufficient contact between the organism and antibiotic. Mixing (or vortexing) at 20 h or continuous 
agitation in a shaker incubator allows for better contact between the organism and antibiotic (CLSI 1999).  
1.6.4.4 Antibiotic carryover 
MBC testing requires the transfer of clear MIC wells onto solid media, and while bacteria is being 
transferred during this step, so is antibiotic. Antibiotic carryover can occur at higher concentrations (>16X 
MIC) and can be detected by inoculating the test broth across the surface of a dried agar plate (allowing 20 
minutes for absorption), then cross-streaking the inoculum over the entire surface of the plate. After 24 h 
of incubation, inhibition of colony growth would be investigated at the site of the initial streak. 
1.6.4.5 Volume transferred 
The volume used to transfer from clear MIC wells should be such that at least 10 colonies are counted after 
99.9% killing; for example, a 99.9% killing endpoint for a starting inoculum of 5 x 105 CFU/mL would be 
100 colonies (CLSI 1999). 
Antibiotic carryover can generate false negative results, particularly if volumes >0.1 mL are being 
transferred, and volumes <0.01 mL can result in too few colonies being transferred. Though the CLSI 
recommend a transfer volume which is between 0.01-0.1 mL, MBC rejection values and the sensitivity and 
specificity of colony counts (which factor pipetting error and Poisson distribution of sample responses) are 
calculated at a transfer volume of 0.01 mL (Pearson, Steigbigel et al. 1980, CLSI 1999). 
1.6.4.6 Choice of media 
Artificial media has little in common with the interstitial fluid of the patient, and the constitution of media 
used can influence the result due to variations in pH, proteins, osmolality, salt concentrations, and divalent 
cations. Therefore, cation-adjusted Mueller-Hinton broth (CAMHB) is recommend for MBC testing as it 
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resembles serum in pH, osmolality and cations, compared to other broth media (CLSI 1999, CLSI 2012). 
The pH should be monitored prior to MBC testing to ensure it is between 7.2 and 7.4. 
1.6.4.7 Effect of storage 
Prolonged storage at temperatures <-70ºC can affect an organism’s ability to retain the tolerance phenotype. 
In some cases the effect of tolerance can diminish, and in others tolerance can be lost entirely (Mayhall and 
Apollo 1980). When taken from storage, the CLSI recommend sub-culturing an isolate three times prior to 
MBC testing (CLSI 1999). 
1.6.5 Method 
As the broth microdilution method is considered the gold standard for the determination of MICs,  therefore, 
MBC testing is also performed using this method. The microdilution method is simple, more efficient, 
reduces the amount of broth needed, and unlike the macrodilution method, adherence of organisms to the 
sides of wells does not appear to be a problem (Taylor, Schoenknecht et al. 1983, Ampel, Keating et al. 
1984). Furthermore, greater reproducibility and reliability is seen in the microdilution method, despite being 
more difficult to determine the 99.9% killing endpoint (Shanholtzer, Peterson et al. 1984).  
MBCs are determined by first performing the standard broth dilution technique for MICs. After 24 h 
incubation any clear wells (i.e. wells demonstrating inhibited growth), are inoculated onto a blood agar 
plate and the number of colonies are recorded. The MBC is determined by a 99.9% reduction of colonies 
compared to the starting concentration (CLSI 1999, Joyce and Woods 2004, Honda, Doern et al. 2011, 
Rose, Fallon et al. 2012), and a bactericidal drug is expected to achieve this within 2 dilutions of the 
organism’s MIC (Joyce and Woods 2004). 
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Figure 1.3 MIC and MBC – Macrodilution method. The MIC is defined by the first clear tube (or well) 
of an antibiotic dilution series, whereas the MBC is defined by the antibiotic concentration in which >99.9% 
bacteria is killed. This figure represents an MIC of 2 µg/mL and MBC of 4 µg/mL, MBC:MIC = 2. Image 
sourced from Finberg et al. (Finberg, Moellering et al. 2004) 
 
1.6.6 Issues with MBC testing 
Despite the attempts to standardise MBC testing (CLSI 1999, Garcia 2010), guidelines still allow for 
variability. For example, to achieve a logarithmic-phase culture the CLSI guidelines recommend S. aureus 
strains are pre-incubated for ‘up to six hours’ prior to testing, despite data showing increased paradoxical 
effect and increased number of survivors when strains are incubated greater than 5 h (Taylor, Schoenknecht 
et al. 1983). Additionally better reproducibility has been demonstrated when the pre-incubation step is set 
at 3 h (May, Shannon et al. 1998). Therefore, unlike MIC testing that has been widely adopted and accepted 
in diagnostic laboratories, MBC testing is viewed with scepticism partly due to the unreliability of methods 
used and lack of confidence in the results obtained (May, Shannon et al. 1998). 
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There are also variations on the definition of antibiotic tolerance. Although vancomycin tolerance is 
generally accepted as vancomycin MBC to MIC ratio of >32 after 24 hours of incubation (Voorn, 
Kuyvenhoven et al. 1994, May, Shannon et al. 1998, CLSI 1999, Sader, Jones et al. 2009, Honda, Doern 
et al. 2011), there have been variations of this definition which include a MBC:MIC ratio of >16 
(Rajashekaraiah, Rice et al. 1980, Honda, Doern et al. 2011), >8 (Gonzalez, Sevillano et al. 2013), or a 
MBC value alone of >16 µg/mL (Sabath, Wheeler et al. 1977).  
Reported rates of vancomycin tolerance among clinical S. aureus strains vary between laboratories and 
range from 4-50% (Reis, Eisencraft et al. 1995, Honda, Doern et al. 2011, Pasticci, Moretti et al. 2011, 
Rose, Fallon et al. 2012, Gonzalez, Sevillano et al. 2013). One study alone showed a variation in the 
prevalence of vancomycin tolerant strains from 20.1% to 24.8%, depending on the numerical definition 
being used (Sader, Jones et al. 2009). Therefore, the variability of MBC test procedures in addition to the 
various definitions used could explain the differences in the proportion of reported tolerant strains. 
Aside from the technical and definition issues, the main criticism of MBC testing is that a 99.9% kill at 24 
hours is an arbitrary endpoint and does not show the rate of kill (Kaye 1980). Time-kill assays instead show 
the true killing response which fits a sigmoidal pattern with a trend for a gradual reduction in the number 
of surviving CFU over time (Liu, Zhang et al. 2004). Time-kill assays also show that the one dimensional 
endpoint associated with MBC testing represents the least accurate part of a kill curve, and that the MBC 
test fails to detect strains that are killed more slowly than others (Sherris 1986). Therefore, time-kill assays 
are considered a more reliable means for determining tolerance in S. aureus (Handwerger and Tomasz 
1985).  
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1.7 Time-kill 
 1.7.1 Principle 
The time-kill assay is a method that can assess the bactericidal activity of an antibiotic, and can establish 
the rate at which an antibiotic kills the isolate (Garcia 2010). Time-kill assays can be used to confirm the 
paradoxical effect, distinguish between tolerance and persistence (Figure 1.4), and can be used to explain 
treatment failures and predict clinical outcome (Brauner, Fridman et al. 2016). However, the disadvantage 
of time-kill assays is that the concentration of antibiotic is fixed over the killing period, which can differ 
from the concentration achieved within a patient during the administering of the antibiotic (Firsov, Zinner 
et al. 2007).  
Compared to the MBC test, there are fewer technical deficiencies and a higher degree of reproducibility in 
a time-kill assay, and time-kills tend to be preferred when determining the bactericidal efficacy of 
vancomycin (May, Shannon et al. 1998, CLSI 1999, Moise, Sakoulas et al. 2007). 
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Figure 1.4 Differentiation between resistance, tolerance and persistence. a) The MIC for a resistant 
strain is much higher than a susceptible strain. In this example the MIC of the resistant strain is 128 µg/mL 
compared to the susceptible strain which is 4 µg/mL. b) The MIC for a tolerant strain is similar to that of a 
susceptible strain (4 µg/mL), however the minimum duration for killing (MDK) of 99% of colonies is 
higher for a tolerant compared to a non-tolerant strain. c) The MIC for a persistent strain is similar to that 
of a susceptible strain (4 µg/mL), however the MDK for 99.9% of colonies is higher for the persistent strain 
when compared to the susceptible strain. Image sourced from Brauner et al. (Brauner, Fridman et al. 2016). 
 
1.7.2 Method 
Time-kill assays are typically performed in glass tubes containing 10 mL of CAMHB with a fixed 
concentration of antibiotic, and another tube without antibiotic which is used as a growth control (CLSI 
1999). The inoculum is prepared similar to that of a MBC test (i.e. logarithmic-phase culture) and must be 
 19 
 
added in a manner that avoids splashing within the tube. Larger vessels such as flasks, beakers and bottles 
allow for a larger volume of broth to be tested and result in a greater challenge to the antimicrobial agent 
and therefore are not recommended (CLSI 1999).  
Whilst the CLSI recommend testing antibiotic concentrations at multiple intervals of the MIC, studies tend 
to favour using a vancomycin concentration of 16 µg/mL, particularly because it reflects the concentration 
that can be achieved in serum (May, Shannon et al. 1998, Aeschlimann, Hershberger et al. 1999, Joyce and 
Woods 2004, Sakoulas, Moise-Broder et al. 2004, Moise, Sakoulas et al. 2007) 
Sampling for colony counts is achieved by removing 0.5 mL samples from the broth at specified times, and 
the CLSI recommend sampling time intervals at 0, 4, 8, 10-12, and 24 h of incubation. Tubes should be 
vortexed before sampling in order to re-suspend bacteria adhering to the wall. Samples are serially diluted 
in 4.5 mL of sterile 0.9% NaCl to produce a dilution series (e.g. 10-1 to 10-4), and no more than 0.1 mL from 
each serial dilution is removed and plated onto a blood agar plate, streaked, and cross-streaked 20 minutes 
later, which determines the CFU/mL (CLSI 1999). Prolonged incubation of the blood agar plate (e.g. 48 h) 
facilitates better colony reading of smaller colonies; some of which the hVISA population are an example 
of (CLSI 1999). 
Recorded colony counts can be charted on semi-log paper, with the survivor colony count on the ordinate 
in logarithmic scale and the time on the abscissa in arithmetic scale (CLSI 1999), but are better represented 
by charting the fraction of survivors over the elapsed time, in hours (Figure 1.5) (May, Shannon et al. 1998, 
Brauner, Fridman et al. 2016). 
 20 
 
 
Figure 1.5 Time kill curves. Killing of S. aureus isolates a) non-tolerant strain 112 and b) tolerant strain 
119 by glycopeptides. The kill rate is monitored over times 0, 2, and 6 hours. Symbols: , growth control; 
, vancomycin (20 µg/mL); , teicoplanin (10 µg/mL). The fraction of survivors is represented by the 
percentage relative count. Image sourced from May et al. (May, Shannon et al. 1998). 
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1.7.3 Issues with time-kill assays 
1.7.3.1 Antibiotic carry-over 
Antibiotic carry-over can be a problem with higher antibiotic concentrations (>4X MIC) and is detected by 
observing for inhibition of growth at the site of inoculation (Figure 1.6). Serial dilutions in saline and drying 
the inoculum on the agar surface before streaking both can reduce the effect of antibiotic carry-over, or 
alternatively bacterial cells can be washed prior to plating. (CLSI 1999). 
 
 
Figure 1.6 Antibiotic carry-over effect. Inoculum containing antibiotic was spread in a blood agar plate. 
a) Allowing the streak to be absorbed into the agar prior to spreading. b) Spread immediately without being 
absorbed. The antibiotic carry-over effect is more noticeable when the inoculum is spread immediately. 
Image sourced from Shanholtzer et al. (Shanholtzer, Peterson et al. 1984). 
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1.7.3.2 Survivors 
Over time, colony counts may increase after an initial decrease which can be due to the selection of resistant 
mutants, inactivation of the antimicrobial agent, or regrowth of susceptible bacterial cells which have 
escaped antimicrobial activity by adhering to glass tube (CLSI 1999). The clinical importance of this 
regrowth is unclear, particularly if it occurs after the usual administered dosing interval of the antibiotic. 
The significance may depend on the time at which regrowth occurs, the dosing of the antibiotic in the 
clinical setting, the type of bacteria, and the antibiotic itself.  
Determining the MIC of survivors will demonstrate if a selection of resistant mutants has occurred, whereas 
assaying the antibiotic potency in the broth at times 0 and 24 h will detect whether the antibiotic has become 
inactivated (CLSI 1999). To detect antibiotic inactivation, MICs can be performed from the 0 and 24 h 
broth with an ATCC control strain and if the MIC increases in the 24 h sample, then the antibiotic has been 
deactivated. 
1.7.3.3 Interpretation of time-kills 
The interpretation of time-kills is difficult, and comparing results of an isolate with another isolate from a 
similar clinical case is the most predictive way to evaluate results (CLSI 1999). Furthermore, there are 
differences in the criteria used to define tolerance using time-kill data. The CLSI for example defines 
tolerance as a < 3-log10 reduction in bacterial count at 24 h (CLSI 1999). May and colleagues however, 
have suggested based on linear regression models a corresponding assessment point (i.e. <2-log reduction 
at 6 h) better represents the true killing rate, prevents false positives secondary to bacterial regrowth of 
isolates which can occur between  6 and 24 h, and prevents false negatives due to loss of nutrients and 
decreased growth (May, Shannon et al. 1998).  
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1.8 Antibiotic tolerance 
 1.8.1 Clinical relevance 
The in vivo clearance rate of bacteraemia caused by S. aureus strains appears to be related to the rate of 
bactericidal killing achieved by vancomycin in vitro (Moise, Sakoulas et al. 2007). Antibiotic tolerance 
results in a lower bactericidal kill and lower percentage of bactericidal activity which adversely affects the 
outcome of serious S. aureus infections treated with vancomycin. In some cases the risk of mortality is 
increased (Sorrell, Packham et al. 1982, Reis, Eisencraft et al. 1995, Aguilar, Gimenez et al. 2009), and in 
other cases additional antibiotics were necessary for cure (Gopal, Bisno et al. 1976, Faville, Zaske et al. 
1978). Inversely, increased bactericidal killing has been associated with rapid clearance of bacteraemia and 
lower all-cause mortality (Sakoulas, Moise-Broder et al. 2004). Tolerance is also significantly more 
common in patients with endocarditis which has been associated with therapeutic failure and increased 
mortality (Denny, Peterson et al. 1979, Kaye 1980, Rajashekaraiah, Rice et al. 1980, May, Shannon et al. 
1998, Pasticci, Moretti et al. 2011), even despite the use of additional antibiotics during therapy (Wilson 
and Gaya 1996).  
 1.8.2 Link between tolerance and reduced susceptibility 
Vancomycin tolerance is more common in MRSA than MSSA strains (May, Shannon et al. 1998). It is 
believed that the PBP2a associated with MRSA strains alters cell wall metabolism, slowing the rate of 
growth, and generates a thickened cell wall. This change in cell wall metabolism is also theorised as the 
mechanism for reduced vancomycin susceptibility in VISA and hVISA strains, and could explain the 
association between vancomycin tolerance and reduced vancomycin susceptibility (Jones 2006, Cazares-
Dominguez, Cruz-Cordova et al. 2015).  
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1.9 Conclusion 
There are no clinical or biological markers which can predict the treatment outcome for patients with MRSA 
bacteraemia, and the mechanism for reduced vancomycin susceptibility is still not completely understood.  
Antibiotic tolerance is a phenotypic trait that allows an organism to survive lethal concentrations of 
vancomycin, and may explain the poor clinical response seen in these patients.   
The ongoing uncertainty about the best methodology has lead clinicians to question the utility of MBC 
testing, and antibiotic tolerance assessment being relegated to “curiosity” status as a consequence. 
However, several studies have observed significantly poorer patient outcomes in infections, especially with 
MRSA isolates, that show vancomycin tolerance (Denny, Peterson et al. 1979, Lodise, Drusano et al. 2014, 
Britt, Patel et al. 2017). With antimicrobial resistance increasing globally and the declining development of 
new and novel antibiotics, a greater emphasis on better usage of current antimicrobials has arisen.  As 
tolerance reflects one component of the spectrum from susceptibility to total resistance, MBC and tolerance 
testing might provide vital information that can inform clinicians and lead to better antibiotics, particularly 
in tolerant S. aureus strains which show susceptibility to vancomycin (Rose, Fallon et al. 2012).  
 
1.10 Scope of Research 
The aim of the study was to investigate the methodology used for tolerance testing with the aim of 
establishing a uniform approach for testing. This study was conducted by investigating the prevalence of 
vancomycin tolerance in an ST239 dominant MRSA population. Isolates were obtained from an organism 
storage library maintained by the Antimicrobial Resistance Mobile Elements Group (ARMEG). This 
culture collection consists of S. aureus isolates collected from patients with sustained bacteraemia, and 
contains a high proportion of VISA/hVISA strains previously confirmed by population-analysis profiling-
area under the curve (PAP-AUC). A series of isolates collected in real-time from patients with sustained S. 
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aureus bloodstream infections were also investigated.  Known tolerant strains supplied from the United 
States (US) (Rose, Fallon et al. 2012) were used as control organisms for MBC testing and time-kill assays. 
The use of different media and test conditions were examined to determine the effect this has on tolerance 
detection. Antibiotic tolerance was determined by MBC testing and time-kill assays. 
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Chapter 2 
Materials and Methods 
 
2.1 Isolates 
Bacterial strains used in this study are listed in Tables 2.1-2.4. 
Retrospective isolates: 67 clinical bloodstream S. aureus strains were isolated from a series of sustained 
bacteraemia episodes (lasting >5 days from onset) seen in patients between 1998 and 2012 at Liverpool 
Hospital, Australia. Phenotypes were previously confirmed by modified population analysis profiling 
(PAP). Three ATCC quality control strains were used as MIC and MBC quality control indicators: 
American Type Culture Collections (ATCC) 29213 which is a vancomycin-susceptible S. aureus (VSSA), 
ATCC 700698, also referred to as Mu3, which is a hVISA, and ATCC 700699, also referred to as Mu50, 
which is a VISA. All of these strains were stored at -80°C.  
Two reported tolerant strains provided by the University of Wisconsin-Madison (Rose, Fallon et al. 2012) 
were used as tolerant positive controls, however the submitting laboratory noted tolerance was lost in both 
strains upon culture from storage. Therefore two separate cultures per strain was received: One set was 
received on Mueller-Hinton agar (MHA) after direct subculture from -80°C storage; isolates Sa0795 (220) 
and Sa0796 (225). Another set, after subculture from -80°C storage, had tolerance induced in vitro by serial 
passage in increasing levels of vancomycin and were then plated onto 2 µg/mL vancomycin-containing 
Mueller-Hinton agar (MHA). These isolates were Sa0793 (220-post) and Sa0794 (225-post). Isolates 
Sa0793 and Sa0795 are from the same parent strain “220”, and Sa0794 and Sa0796 are from the same 
parent strain “225”.  
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Prospective isolates: Bloodstream S. aureus strains isolated from patients with sustained bacteraemia 
(lasting >5 days from onset) between 2013 and 2014 in Royal Prince Alfred Hospital (RPAH), 
Camperdown Australia. Isolates were collected in real time and were tested prior to being stored at -80ºC.  
Isolates taken from -80ºC storage were subcultured three times on horse blood agar (HBA) (Edwards Group, 
Narellan NSW, AU) prior to testing, as recommended by CLSI guidelines. All tests were performed in 
duplicate unless indicated, and in the setting of multiple tests, all results indicate the average result. 
 
Table 2.1 S. aureus isolates – Clinical strains isolated from patients in Liverpool Hospital. 
Isolate 
Number 
Isolate Type Phenotype1  Isolate 
Number 
Isolate Type Phenotype1 
Sa0012 Recurrent hVISA  Sa0116 Recurrent VSSA 
Sa0016 Initial hVISA  Sa0129 Initial VSSA 
Sa0018 Recurrent hVISA  Sa0131 Recurrent VSSA 
Sa0020 Persistent hVISA  Sa0134 Initial VSSA 
Sa0021 Persistent hVISA  Sa0138 Initial VSSA 
Sa0022 Persistent VSSA  Sa0158 Initial VSSA 
Sa0037 Initial hVISA  Sa0160 Persistent VSSA 
Sa0040 Initial hVISA  Sa0162 Persistent VSSA 
Sa0044 Recurrent hVISA  Sa0164 Persistent VSSA 
Sa0047 Persistent VSSA  Sa0192 Persistent VSSA 
Sa0048 Initial VSSA  Sa0202 Persistent VSSA 
Sa0049 Persistent VSSA  Sa0209 Initial VSSA 
Sa0050 Persistent hVISA  Sa0210 Persistent VSSA 
Sa0051 Initial hVISA  Sa0211 Persistent VSSA 
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Sa0052 Persistent hVISA  Sa0212 Initial VSSA 
Sa0053 Initial VSSA  Sa0214 Recurrent VSSA 
Sa0055 Initial VSSA  Sa0228 Initial VSSA 
Sa0056 Recurrent hVISA  Sa0265 Persistent VSSA 
Sa0057 Initial VSSA  Sa0283 Initial VSSA 
Sa0058 Persistent hVISA  Sa0294 Initial VSSA 
Sa0059 Persistent VISA  Sa0308 Recurrent VSSA 
Sa0060 Persistent hVISA  Sa0322 Initial VSSA 
Sa0061 Initial hVISA  Sa0323 Initial VSSA 
Sa0062 Persistent hVISA  Sa0324 Persistent VSSA 
Sa0063 Initial hVISA  Sa0325 Persistent VSSA 
Sa0064 Initial hVISA  Sa0329 Initial VSSA 
Sa0065 Initial hVISA  Sa0330 Recurrent VSSA 
Sa0066 Initial VISA  Sa0331 Initial VSSA 
Sa0067 Recurrent hVISA  Sa0332 Persistent VSSA 
Sa0068 Initial hVISA  Sa0363 Initial VSSA 
Sa0069 Recurrent VSSA  Sa0375 Persistent VISA 
Sa0070 Recurrent hVISA  Sa0378 Persistent VISA 
Sa0091 Initial VSSA  Sa0484 Unknown VSSA 
Sa0112 Recurrent VSSA     
1Abbreviations: VSSA, (vancomycin-susceptible S. aureus); VISA, (vancomycin-intermediate S. aureus); 
hVISA, (heterogenous vancomycin-intermediate S. aureus) 
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Table 2.2 S. aureus isolates – Quality control strains. 
Organism Name Isolate Number Phenotype1 Source 
S. aureus ATCC 29213 VSSA American Type Culture Collections 
Mu3 ATCC 700698 hVISA American Type Culture Collections 
Mu50 ATCC 700699 VISA American Type Culture Collections 
1Abbreviations: VSSA, (vancomycin-susceptible S. aureus); VISA, (vancomycin-intermediate S. aureus); 
hVISA, (heterogenous vancomycin-intermediate S. aureus) 
 
Table 2.3 S. aureus isolates – Reported tolerant strains. 
Organism Name Isolate Number Source Comments1 
220-post Sa0793 
University of 
Wisconsin-
Madison 
Pre-exposed to sub-lethal concentrations 
of vancomycin; cultured on MHA 
containing 2 µg/mL vancomycin 
220 Sa0795 
University of 
Wisconsin-
Madison 
Cultured on MHA 
225-post Sa0794 
University of 
Wisconsin-
Madison 
Pre-exposed to sub-lethal concentrations 
of vancomycin; cultured on MHA 
containing 2 µg/mL vancomycin 
225 Sa0796 
University of 
Wisconsin-
Madison 
Cultured on MHA 
1Abbreviations: MHA, (Mueller-Hinton agar) 
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Table 2.4 S. aureus isolates – Clinical strains isolated from patients in RPAH. 
Series Isolate Number Isolate Type 
A Sa0744 Initial 
A Sa0745 Persistent 
A Sa0746 Persistent 
A Sa0747 Persistent 
A Sa0748 Persistent 
A Sa0749 Persistent 
A Sa0750 Persistent 
A Sa0751 Persistent 
B Sa0752 Initial 
B Sa0753 Persistent 
B Sa0754 Persistent 
B Sa0755 Persistent 
B Sa0756 Persistent 
B Sa0757 Persistent 
C Sa0758 Initial 
C Sa0759 Persistent 
C Sa0760 Persistent 
C Sa0761 Persistent 
C Sa0762 Persistent 
C Sa0763 Persistent 
C Sa0764 Persistent 
C Sa0765 Persistent 
C Sa0766 Persistent 
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2.2 Antibiotic, reagents and media 
Vancomycin was purchased from a commercial source (Sigma-Aldrich., St. Louis, MO, USA). Brain-Heart 
infusion broth (BHIB) and Brain-Heart infusion agar (BHIA) (Oxoid Limited, Basingstoke, Hampshire, 
UK) were prepared as per manufacturer’s instructions. Mueller-Hinton broth (MHB) (Oxoid Limited, 
Basingstoke, Hampshire, UK) was monitored with a pH meter prior to testing and supplemented with 20-
25 mg/L calcium and 10-12.5 mg/L magnesium to ensure the pH was between 7.2-7.4. MHB with a pH 
reading outside this range was not used. Commercially prepared HBA and in-house prepared Luria broth 
agar (LBA) were used as solid plate media. Compositions for media used are listed in Table 2.5. Reagents 
and solutions used as well as their compositions are listed in Table 2.6. 
Table 2.5 Bacteriological media. 
Media Composition Reference 
Brain-Heart Infusion agar 
(BHIA) 
1.25% Brain infusion solids  
0.5% Beef heart infusion solids  
1% Proteose peptone 
0.2% Glucose 
0.5% Sodium choride 
0.25% Disodium phosphate 
1% Agar 
Oxoid Limited 
(Hampshire, UK) 
Brain-Heart Infusion broth 
(BHIB) 
1.25% Brain infusion solids  
0.5% Beef heart infusion solids  
1% Proteose peptone 
0.2% Glucose 
0.5% Sodium choride 
0.25% Disodium phosphate 
Oxoid Limited 
(Hampshire, UK) 
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Luria-Bertani agar (LBA) 
1 % NaCl  
1 % Tryptone  
0.5 % Yeast Extract 
1.2% Agar 
Willets and Finnegan 1970 
Luria-Bertani broth (LBB) 
1 % NaCl  
1 % Tryptone  
0.5 % Yeast Extract 
Willets and Finnegan 1970 
Mueller-Hinton broth (MHB) 
3% Beef Extract  
17.5% Casein Hydrolysate  
1.5% Starch 
Oxoid Limited 
(Hampshire, UK) 
Trypticase Soy broth (TSB) 
0.25% Glucose 
0.17% Peptone 
0.3% Peptone, soy 
0.25% di-Potassium bis orthophosphate 
0.5% NaCl 
Becton Dickinson 
(New Jersey, US) 
 
 
Table 2.6 Buffers and reagents. 
Buffer/Reagent Composition 
1 M Calcium Chloride 1.672 g / 20 mL 
1 M Magnesium Chloride 0.736 g / 20 mL  
McFarland reference standard 0.5 
Saline 0.90% NaCl 
Vancomycin stock concentration 2,560 µg / mL 
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Vancomycin stock concentration was determined as described in the CLSI Methods for Dilution 
Antimicrobial Susceptibility Tests, M07-A9 (CLSI 2012): 
Weight (mg) = Volume (mL) x Concentration (µg/mL) 
Potency (µg/mL) 
As per manufacturer’s certificate of analysis, the potency of vancomycin power was 996 µg/mL.  
Weight (mg) = 10 mL x 2,560 µg/mL 
996 
Therefore 25.7 mg vancomycin power was added to 10 mL of MilliQ water to achieve a final vancomycin 
stock concentration of 2,560 µg / mL. This stock solution was aliquoted and stored for no more than 6 
months at -20ºC. This vancomycin solution was further diluted to required concentrations and any unused 
aliquots were discarded after use. 
 
2.3 Population-analysis profiling 
Modified PAP-AUC as described by Wooten et al (Wootton, Howe et al. 2001) was used to determine the 
phenotypes for the three ATCC quality controls and the reported vancomycin tolerant control strains listed 
in Table 2.3. Cultures were incubated for 24 h at 37ºC in trypticase soy broth (TSB). After incubation, 
cultures were diluted to 10-3 and 10-6 in 0.9% sterile saline and plated on vancomycin-containing BHIA 
containing 0.5, 1, 2, 2.5, 4, 8, and 16 µg/mL vancomycin. After 48 h incubation at 37ºC, colonies were 
counted and plotted against the respective vancomycin concentration using Microsoft Excel (Microsoft 
Corporation; Redmond, Washington, USA). The area under the curve (AUC) was calculated for each isolate 
and the AUC ratio was determined by dividing an organism’s AUC by the AUC for Mu3. An AUC:Mu3 
ratio of >0.9 to <1.3 was used as the criteria for determining a hVISA phenotype, and a ratio of >1.3 was 
used as the criteria for a VISA (Howden, Davies et al. 2010).  
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A purity plate subculture, antibiotic control and negative control were used for all PAP-AUC tests. Results 
were deemed invalid if there was growth in the antibiotic or negative control, or if the purity plate contained 
mixed growth. 
 
2.4 Time-kill studies 
Time-kill studies were performed as per CLSI guidelines. 5-30 colonies obtained from an overnight HBA 
culture were suspended in pre-warmed MHB, shaken at 160 rpm and incubated for 3 h at 37°C to ensure 
logarithmic-phase growth. The turbidity was adjusted with MHB to 0.5 McFarland standard, which was 
then further diluted in 0.9% saline to achieve a 1-9 x 105 cfu/mL concentration in 10 mL MHB with and 
without vancomycin. Isolates inoculated in MHB without vancomycin acted as a growth controls. Cultures 
were shaken at 160 rpm at 37°C and incubated for 24 h. At times 0, 4, 8, 10, and 24 h and with appropriate 
dilutions in saline (0.5 mL from each suspension diluted in 4.5 mL saline), 100 µl from each diluted 
suspension was plated onto an agar plate and incubated for 48 h at 37°C. Colony counts were assessed and 
viable counts (in cfu/mL) were then plotted against time (in h) in Microsoft Excel. The rate of kill for each 
isolate was subsequently determined as previously described (May, Shannon et al. 1998, Aeschlimann, 
Hershberger et al. 1999), using linear regression on the observed time-kill plot with forward prediction to 
estimate the minimum duration to kill 99% of the bacterial population (also known as the MDK90) (Brauner, 
Fridman et al. 2016). This was assessed against the CLSI definition of tolerance, being a < 3-log10 reduction 
in bacterial count at 24 h (CLSI 1999).  
A purity plate subculture, antibiotic control and negative control were used for each assay. Results were 
deemed invalid if there was growth in the antibiotic or negative control, or if the purity plate contained 
mixed growth. The growth control was monitored by colony counts of the MHB suspension at the above 
specified time points. Antibiotic carry-over streaks were performed at time 0 h for each isolate: 0.1mL of 
the inoculated vancomycin-containing CAMHB was plated on solid media. After 15 mins, allowing for the 
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absorption of antibiotic into the agar, the plate was cross-streaked. After 48 h of incubation at 35ºC, plates 
were inspected for signs of inhibition at the initial streak in order to determine antibiotic carry-over. 
 
2.5 MIC/MBC test 
Vancomycin MICs/MBCs were determined by broth microdilution as per current CLSI guidelines. 5-30 
colonies obtained from an overnight HBA culture were suspended in pre-warmed MHB, and shaken at 160 
rpm and incubated for 3 h at 37°C to ensure logarithmic-phase growth. The turbidity was adjusted with 
MHB to 0.5 McFarland standard, which was then further diluted in 0.9% saline to achieve a final 
concentration of 5 x 105 cfu/mL. 0.01 mL of this final concentration was inoculated in a microtitre tray 
containing MHB and serial dilutions of vancomycin ranging from 0.5-128 µg/mL (Table 2.7). After 
inoculation, 0.01 mL from the growth control well was serially diluted in 0.9% sterile saline and plated on 
to a HBA agar plate to accurately determine the number of cfu/mL. Plates were incubated at 37°C for 48 h. 
Microtitre trays, stacked no more than four high, were incubated for 24 h at 37°C. All trays were shaken to 
dislodge any organisms adhering above the meniscus of each well at 20 h. The first well with no visible 
growth (i.e. the MIC) for each organism was recorded at 24 h.  10 µL of this well and all other clear wells 
were inoculated and spread onto an agar plate and incubated for 48 h at 37°C. Viable counts were calculated 
to give cfu/mL and the 99.9% endpoint for bactericidal activity was determined by the starting 
concentration (Table 2.8). Tolerance was defined as a MBC:MIC ratio of >32 unless indicated otherwise. 
For Mu50, due to the high starting MIC (8 µg/mL) and the vancomycin concentration endpoint of 128 
µg/mL, a MBC/MIC ratio of >16, was accepted as indicative of tolerance provided there was sufficient 
growth at 24 h.  
A purity plate subculture, antibiotic control, growth control and negative control were used for each assay. 
Results were deemed invalid if there was growth in the antibiotic or negative control, or if the growth 
control was clear, or if the purity plate contained mixed growth. 
 36 
 
Table 2.7 MIC/MBC Microtiter tray. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A – Isolate 1 AC 
V 
(128) 
V/2 
(64) 
V/4 
(32) 
V/8 
(16) 
V/16 
(8) 
V/32 
(4) 
V/64 
(2) 
V/128 
(1) 
V/256 
(0.5) 
GC NC 
B – Isolate 1 AC V V/2 V/4 V/8 V/16 V/32 V/64 V/128 V/256 GC NC 
C – Isolate 2 AC V V/2 V/4 V/8 V/16 V/32 V/64 V/128 V/256 GC NC 
D – Isolate 2 AC V V/2 V/4 V/8 V/16 V/32 V/64 V/128 V/256 GC NC 
E – Isolate 3 AC V V/2 V/4 V/8 V/16 V/32 V/64 V/128 V/256 GC NC 
F – Isolate 3 AC V V/2 V/4 V/8 V/16 V/32 V/64 V/128 V/256 GC NC 
G – Isolate 4 AC V V/2 V/4 V/8 V/16 V/32 V/64 V/128 V/256 GC NC 
H – Isolate 4 AC V V/2 V/4 V/8 V/16 V/32 V/64 V/128 V/256 GC NC 
Abbreviations: AC, (antibiotic control); V, (128 µg/mL vancomycin); GC, (growth control); NC, (negative 
control) 
0.01 mL of the 1-9 x 105 cfu/mL organism suspension was inoculated in columns 2-11.  
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Table 2.8 MBC rejection values based off a single 0.01mL samplea. 
Includes 5% pipette plus full sampling error for determination of final inoculumb 
Final 
Inoculum 
(CFU/ml) 
Rejection 
Valuec 
Sensitivityd 
(%) 
Specificityd 
(%) 
1 x 105 3 84 83 
2 x 105 4 87 97 
3 x 105 6 84 98 
4 x 105 8 89 99 
5 x 105 11 96 99 
6 x 105 15 99 99 
7 x 105 17 99 99 
8 x 105 20 99 99 
9 x 105 23 99 99 
1 x 106 25 99 99 
2 x 106 47 87 99 
3 x 106 68 84 99 
4 x 106 91 89 99 
5 x 106 113 96 99 
6 x 106 136 99 99 
7 x 106 159 99 99 
8 x 106 182 99 99 
9 x 106 204 99 99 
1 x 107 227 99 99 
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a When the number of colonies from a single sample was equal to or less than the rejection value, the 
antibiotic was declared lethal (0.999 or greater reduction in the final inoculum). 
b Based on a single sample for the determination of the final inoculum size. 
c Number of colonies. 
d Sensitivity and specificity calculated for each specific final inoculum concentration and rejection value. 
Table sourced from CLSI (CLSI 1999) 
 
 
2.6 Modified MBC test – gradual vancomycin exposure to organism MIC 
A vancomycin pre-exposure step was used as an experimental modification to the CLSI method. Prior to 
MIC/MBC testing isolates were passaged for 3 days at 37ºC in doubling concentrations of vancomycin 
every 24 h in BHI broth, starting at dilutions below the measured MIC (i.e. 1/8; 1/4; 1/2; of MIC), followed 
by daily passage for 3 further days at the measured MIC. All broth cultures were shaken at 160 rpm. The 
final suspension was plated onto BHIA containing vancomycin equivalent to the final concentration 
obtained in the BHIB and incubated at 37ºC for 24 h. MIC/MBC testing was performed as described in 
Section 2.5 by taking 5-30 colonies from this BHIA plate.  
Table 2.9 Vancomycin passage algorithm. 
Isolate 
Number 
Day 1 
MIC1 
Day 2 
MIC1 
Day 3 
MIC1 
Days 4-6 
MIC1 
Day 7 
MIC2 
Isolate A V/8 V/4 V/2 V V 
1MIC, (minimum inhibitory concentration); V, (vancomycin concentration (µg/mL), determined by 
previously obtained MIC results) 
2Cultured on BHIA containing final vancomycin concentration 
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2.7 Modified MBC test – 0.5x vancomycin MIC 
A vancomycin pre-exposure step was used as an experimental modification to the CLSI method. Isolates 
were exposed to a vancomycin concentration of half the organism’s measured MIC for 24 h at 37ºC in BHI 
broth, shaken at 160 rpm. The final suspension was plated onto BHIA containing vancomycin equivalent 
to the final concentration obtained in the BHIB and incubated at 37ºC for 24 h. These series of isolates were 
also incubated in BHI without vancomycin which acted as test controls. MIC/MBC testing was performed 
as described in Section 2.5 by taking 5-30 colonies from the BHIA and BHIA with vancomycin plates. 
 
2.8 Modified MBC test – pre-enrichment step 
A nutrient media enrichment step was used as an experimental modification to the CLSI method. Colonies 
were suspended in BHIB and shaken at 160 rpm and incubated at 37ºC for 24 h. The final suspension was 
plated onto BHIA and incubated at 37ºC for 24 h. MIC/MBC testing was performed as described in Section 
2.5 by taking 5-30 colonies from this BHIA plate.  
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Chapter 3 
Results 
Population-analysis-profiling 
 
3.1 Introduction 
Routine susceptibility testing does not reliably detect hVISA/VISA strains, and population-analysis-profile 
area under the curve (PAP-AUC) as described by Wootton et al.(Wootton, Howe et al. 2001) is considered 
the gold standard for confirming the phenotype for hVISA strains, despite not being used in routine clinical 
laboratories (Aeschlimann, Hershberger et al. 1999, Sader, Jones et al. 2009, Kullar, Davis et al. 2011). 
Therefore, PAP-AUC was used to determine the phenotypes for all ATCC controls used in this study and 
the supplied S. aureus tolerant strains described in Table 2.3. 
 
3.2 Population analysis profile confirms phenotypes 
Strains 29213, Sa0795 and Sa0796 were non-viable at vancomycin concentrations of 2µg/mL (Figure 3.1). 
Mu3 demonstrated hetero-resistance, with half of the population surviving at a vancomycin concentration 
of 2.5 µg/mL and there were no surviving colonies beyond 4 µg/mL vancomycin. The population profile 
for Mu50 showed consistently high counts until the vancomycin concentration reached 8 µg/mL. The 
population for Sa0793 and Sa0794 ranged between Mu3 and Mu50; the majority of the population remained 
until the vancomycin concentration reached 4 µg/mL.  The counts for these strains dropped to 0 cfu/mL in 
vancomycin concentrations of 4-8 µg/mL.  
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PAP-AUC results for the ATCC strains confirmed their respective phenotypes: ATCC 29213, 700698 
(Mu3) and 700699 (Mu50) had a PAP-AUC of 0.43, 1, and 2.52 and were confirmed as VSSA, hVISA and 
VISA strains respectively.  
Different PAP-AUC results were seen in the supplied tolerant strains, and the PAP-AUC varied depending 
on whether the isolates were passaged in vancomycin prior to PAP testing (Table 3.1). Sa0795 and Sa0796 
(strains 220 and 225 which were cultivated on MHA directly from -80ºC storage) had AUC:Mu3 ratios that 
were <0.9 (0.46; both isolates) and were classified as VSSA strains. Sa0793 and Sa0794 (strains 220-post 
and 225-post, which underwent vancomycin passage and were cultivated on vancomycin-containing MHA, 
were both classified as VISA strains, albeit Sa0794 was close to the VISA cut-off of 1.3 (2.22, 1.31 
AUC:Mu3 ratios respectively). 
 
Table 3.1 Area under the curve.  
Isolate Number Isolate Name AUC AUC:Mu3 
PAP-AUC 
Identification1 
ATCC 29213 S. aureus 7.90 0.43 VSSA 
ATCC 700698 Mu3 18.50 1 hVISA 
ATCC 700699 Mu50 46.52 2.52 VISA 
Sa0795 220 8.60 0.46 VSSA 
Sa0793 220-post 41.05 2.22 VISA 
Sa0796 225 8.48 0.46 VSSA 
Sa0794 225-post 24.21 1.31 VISA 
1Abbreviations: VSSA, (vancomycin-susceptible S. aureus); VISA, (vancomycin-intermediate S. aureus); 
hVISA, (heterogenous vancomycin-intermediate S. aureus) 
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Figure 3.1 Population analysis profile. Log10 cfu grown in the presence of vancomycin for the ATCC 
quality control strains and the known tolerant strains. Isolates tested in duplicate. 
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Chapter 4 
Results 
Time-kills 
 
4.1 Introduction 
Time-kills are considered a more reliable test for determining tolerance, as the time-kill curve technique 
determines the actual rate which bacteria are killed, but also has the best correlation with overall cure (CLSI 
1999). There are variations in interpreting a time-kill curve, with the CLSI defining tolerance as < 3-log10 
reduction in bacterial count at 24 h, while other studies suggest determining the reduction in bacterial count 
within the first 6-8 h, and using a threshold of line of regression and calculating the kill at 6 h  (May, 
Shannon et al. 1998). 
 
4.2 Determining the vancomycin concentration for time kills 
Time kills were performed on a representative VSSA (Sa0484 – clinical strain), hVISA (Mu3) and VISA 
strain (Mu50) and were performed at 1X, 2X, 4X, and 8X the organism’s respective MIC, determined by 
previous MIC tests (Figure 4.1).  
Bacterial regrowth was seen in the VSSA strain Sa0484 at 1X vancomycin MIC (24 h time point) and 2X 
vancomycin MIC (12 h time point). There was no difference in killing when the concentration was at 4X 
(8 µg/mL) and 8X (16 µg/mL) vancomycin MIC. 
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Time kills performed at 1X-2X vancomycin MIC for the hVISA strain Mu3 demonstrated reduced efficacy 
of vancomycin killing, indicating that the sub-population of VISA strains were resisting the bactericidal 
activity of vancomycin at these concentrations, and that a minimum vancomycin concentration of >8 µg/mL 
is required for killing. There was no difference in killing of Mu3 at vancomycin concentrations of > 8 
µg/mL. 
There was no significant difference in killing of the VISA strain Mu50, irrespective of the vancomycin 
concentration used.  
These time-kill results demonstrate that the effect of vancomycin killing is unchanged once the vancomycin 
concentration is > 16 µg/mL, irrespective of whether the strain is a VSSA, hVISA or VISA isolate. As 
vancomycin concentrations of 16 µg/mL are used in other time kill studies (May, Shannon et al. 1998, 
Sakoulas, Moise-Broder et al. 2004, Moise, Sakoulas et al. 2007), this therefore was used for further time-
kill tests in this study.  
Checks for antibiotic carry-over in all vancomycin concentrations used showed no zones of clearing. By 
allowing 15 minutes for antibiotic absorption into the agar, this indicated antibiotic carry-over was not a 
problem, even when the vancomycin concentrations were 8X the organism’s MIC. Therefore no additional 
inactivation or wash steps were necessary. 
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Figure 4.1 Time-kill data for S. aureus strains grown in various vancomycin concentrations. Isolates Sa0484 (VSSA) (a), Mu3 (hVISA) (b), 
and Mu50 (VISA) (c). Kill rate monitored over times 0, 4, 8, 12, and 24 hours.
Legend 
  µg/mL 
vancomycin 
 Concentration (a) (b)   (c)   
 1X MIC 2 2 8 
 2X MIC 4 4 16 
 4X MIC 8 8 32 
 8X MIC 16 16 64 
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4.3 Time-kills 
Time-kills were performed on ATCC control strains 29213 (VSSA), Mu3 (hVISA), Mu50 (VISA), tolerant 
strains Sa0793 (220-post), Sa0794 (225-post) (VISA), and clinical strain Sa0066 (VISA). Time-kills were 
performed at a fixed vancomycin concentration of 16 µg/mL (Figure 4.2). Checks for antibiotic carry-over 
were performed and was not detected. 
Time kills demonstrated that VISA isolates were killed significantly slower than VSSA and hVISA isolates. 
Tolerance was only confirmed in a single isolate (Sa066) using the CLSI’s definition of tolerance, with 
1.56% viable colonies remaining from the starting inoculum at 24 h (Table 4.1). In contrast, using the 
MDK90 of 6 h confirmed that all the reduced vancomycin susceptible isolates were tolerant with the 
proportion of surviving colonies of Mu3, Mu50, Sa0066, Sa0793 and Sa0794 of 10.77, 21.4, 41.84, 26.6 
and 15.24% respectively. The VSSA strain was close to the cut-off for tolerance, with 9.99% viable colonies 
at 6 h. This data suggests the utility of using the MDK90 for defining tolerance, especially given the 
prevalence of tolerance seen in VISA and hVISA isolates (Jones 2006, Cazares-Dominguez, Cruz-Cordova 
et al. 2015).  
Table 4.1: Time-kill counts for isolates 29213, Mu3, Mu50, Sa0066, Sa0793 and Sa0794. 
Time (h) 
Percentage of viable colonies (%) 
29213 Mu3 Mu50 Sa0066 Sa0793 Sa0794 
0 100 100 100 100 100 100 
4 18.05 17.59 33.69 59.56 43.90 26.98 
6a 9.99 10.77 21.40 41.84 26.60 15.24 
8 1.88 4.00 9.08 24.13 9.24 3.50 
10 0.23 0.52 4.26 11.78 4.08 2.83 
24 0.01 0.03 0.05 1.56 0.08 0.05 
aCount at 6 h was extrapolated using linear regression between times 4 and 8 h. 
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Legend 
 Isolate 
Number 
Phenotype 
Tolerance 
MDK90 (A) CLSI (B) 
 29213 VSSA NO NO 
 Mu3 hVISA YES NO 
 Mu50 VISA YES NO 
 Sa0066 VISA YES YES 
 Sa0793 VISA YES NO 
 Sa0794 VISA YES NO 
 
Figure 4.2 Time-kill data for S. aureus strains. VSSA: vancomycin susceptible S. aureus; hVISA: 
heterogeneous vancomycin intermediate S. aureus; VISA: vancomycin intermediate S. aureus. Kill rate 
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was monitored over times 0, 4, 8, 10, and 24 hours. Count at 6 h was extrapolated using linear regression 
between times 4 and 8 h. 
An isolate is regarded as tolerant by the CLSI if there was less than 3 log reduction in bacterial population 
at 24 h following exposure to an antibiotic (depicted by point B); an alternate definition is an MDK90 of 
greater than 6 h, as suggested by May et. al. (depicted by point A). 
 
4.4 Time-kills - comparing alternative solid media 
CLSI recommend using HBA for MBC and time-kill testing, but some studies use media other than HBA 
(Table 10.1). To ascertain whether the choice of solid media affects the ability to detect tolerance, Luria 
broth agar (LBA), an inexpensive plate medium commonly used for the cultivation of bacteria, was used 
as a comparator against HBA. Time-kills were performed on ATCC control strains 29213 (VSSA), Mu3 
(hVISA) and Mu50 (VISA) at a fixed vancomycin concentration of 16 µg/mL (Figure 4.3). Checks for 
antibiotic carry-over were performed and was not detected, irrespective of the plate media used. 
Using the CLSI definition, isolates Mu3 and Mu50 were tolerant when plated on HBA, with 0.22% and 
0.13% viable colonies remaining at 24 h (Table 4.2). In contrast, these same strains showed 0.02% viable 
colonies remaining at 24 h when plated on LBA, classifying them as non-tolerant. Isolate 29213 showed 
0.08% and 0.02% remaining colonies at 24 h when plated on HBA and LBA respectively, demonstrating 
non-tolerance irrespective of the plate media used. 
With the exception of a singular 4 h time point for isolate 29213 (HBA: 14.5% viable colonies; LBA: 
14.8%), the number of viable colonies were lower for all strains when plated on LBA compared to HBA 
(Table 4.2). This was marked for Mu50, a known VISA strain, comparing HBA versus LBA at 4 h (60.6% 
versus 44.25% respectively), at 6 h (50.27% versus 29.37%), 8 h (39.91% versus 14.55%), and 24 h (0.13% 
versus 0.02%) yielded a large disparity between the number of remaining survivors at each time point.  
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Overall, these lower counts did not impact the classification of tolerance when using the MDK90 of 6 h as 
the criteria for tolerance. Isolates Mu3 and Mu50 were classified as tolerant and isolate 29213 was non-
tolerant when using the MDK90 of 6 h, irrespective of the plate media used.  
 
Table 4.2: Time-kill counts for isolates plated on HBA and LBA. 
Time (h) 
Percentage of viable colonies (%) 
29213 Mu3 Mu50 
HBA1 LBA1 HBA1 LBA1 HBA1 LBA1 
0 100 100 100 100 100 100 
4 14.50 14.80 43.68 29.38 60.62 44.25 
6a 9.29 9.08 27.05 19.27 50.27 29.37 
8 3.95 3.36 10.43 9.17 39.91 14.55 
24 0.08 0.02 0.22 0.02 0.13 0.02 
1Abbreviations: HBA, (horse blood agar); LBA, (Luria broth agar);  
aCount at 6 h was extrapolated using linear regression between times 4 and 8 h. 
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 Legend 
 Isolate 
Number 
Solid 
media 
Phenotype 
Tolerance 
MDK90 (A) CLSI (B) 
 29213 
HBA 
VSSA NO NO 
 Mu3 hVISA YES YES 
 Mu50 VISA YES YES 
 29213 
LBA 
VSSA NO NO 
 Mu3 hVISA YES NO 
 Mu50 VISA YES NO 
 
Figure 4.3 Time-kill data for S. aureus strains plated on HBA and LBA. VSSA: vancomycin susceptible 
S. aureus; hVISA: heterogeneous vancomycin intermediate S. aureus; VISA: vancomycin intermediate S. 
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aureus; LBA: Luria broth agar; HBA: Horse blood agar. Kill rate was monitored over times 0, 4, 8, and 24 
hours. Count at 6 h was extrapolated using linear regression between times 4 and 8 h. 
An isolate is regarded as tolerant by the CLSI if there was greater than a 3 log reduction in bacterial 
population at 24 h following exposure to an antibiotic (depicted by point B); an alternate definition is an 
MDK90 of greater than 6 h, as suggested by May et. al. (depicted by point A). 
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Chapter 5 
Results 
MIC/MBC 
5.1 Introduction 
MIC testing is well standardised and accepted in clinical laboratories, and the microdilution method was 
used in this study.  
The CLSI recommend an “up to 6 hours for staphylococci” pre-incubation step for MBC testing (CLSI 
1999). However greater variability is seen when a 4-5 h pre-incubation step is used, and studies suggest the 
use of a mid-log phase culture which is typically achieved in 3 h (Taylor, Schoenknecht et al. 1983, May, 
Shannon et al. 1998, Harris, Foster et al. 2002). For this reason a 3 h pre-enrichment step was used for all 
of the MIC/MBC tests. 
 
5.2 Tolerance not readily detected when using the CLSI method 
In addition to 3 ATCC strains, a total of 63 MRSA strains isolated from patients with sustained bacteraemia 
seen in Liverpool Hospital were tested for MIC and MBC (Table 5.1). All strains were retrieved from -
80ºC storage, and the MICs obtained for all strains replicated MIC results obtained from prior clinical tests, 
and also matched the respective phenotype which was previously determined by PAP-AUC. The MBCs 
obtained were largely within 1-2 dilutions of the organism’s MIC, and with the exception of Mu50 and 
Sa0060, tolerance was not seen in these series of isolates. While Mu50 and Sa0060 displayed raised 
MBC:MIC ratios (16; both isolates), tolerance in these two strains was not readily detected (Mu50: tolerant 
in 1 of 4 tests: 25% tolerance rate; Sa0060: tolerant in 1 of 2 tests: 50% tolerance rate).  
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Table 5.1 Tolerance testing CLSI method.  
Isolate 
Number 
Phenotype1 MIC1 MBC1 MBC/
MIC1 
No. 1 Tolerant 
% (n) 1 
29213 VSSA 1-2 1-2 1-2 4 0 (0) 
Mu3 hVISA 2 4 2 4 0 (0) 
Mu50 VISA 8-16 8-128 1-16 4 25 (1) 
Sa0012 hVISA 4 4 1 2 0 (0) 
Sa0016 hVISA 2 4-8 2-4 2 0 (0) 
Sa0018 hVISA 4 8 2 2 0 (0) 
Sa0020 hVISA 4 4 1 2 0 (0) 
Sa0021 hVISA 4 4 1 2 0 (0) 
Sa0022 VSSA 2 4 2 2 0 (0) 
Sa0037 hVISA 4 4 1 2 0 (0) 
Sa0040 hVISA 4 4 1 2 0 (0) 
Sa0044 hVISA 4 4 1 2 0 (0) 
Sa0047 VSSA 2 2-4 1-2 2 0 (0) 
Sa0048 VSSA 2 2-4 1-2 2 0 (0) 
Sa0049 VSSA 2 2 1 2 0 (0) 
Sa0050 hVISA 2 4 2 2 0 (0) 
Sa0051 hVISA 4 4 1 2 0 (0) 
Sa0052 hVISA 2 4 2 2 0 (0) 
Sa0053 VSSA 2 2-4 1-2 2 0 (0) 
Sa0057 VSSA 2 2-4 1-2 2 0 (0) 
Sa0058 hVISA 4 4 1 2 0 (0) 
Sa0059 VISA 4 8 2 2 0 (0) 
 54 
 
Sa0060 hVISA 8 8-128 16 2 50 (1) 
Sa0062 hVISA 1-2 2-4 1-4 2 0 (0) 
Sa0063 hVISA 2 4 2 2 0 (0) 
Sa0064 hVISA 2 4 2 2 0 (0) 
Sa0066 VISA 4 8-16 2-4 2 0 (0) 
Sa0067 hVISA 4 4-8 1-2 2 0 (0) 
Sa0068 hVISA 4 4 1 2 0 (0) 
Sa0069 VSSA 1 2-4 2-4 2 0 (0) 
Sa0070 hVISA 2-4 4-8 1-4 2 0 (0) 
Sa0091 VSSA 1 2 2 2 0 (0) 
Sa0112 VSSA 2 2 1 2 0 (0) 
Sa0116 VSSA 2 2 1 2 0 (0) 
Sa0129 VSSA 0.5-1 1 1-2 2 0 (0) 
Sa0131 VSSA 1 2 2 2 0 (0) 
Sa0134 VSSA 1 2 2 2 0 (0) 
Sa0138 VSSA 2 2-4 1-2 2 0 (0) 
Sa0158 VSSA 1 2 2 2 0 (0) 
Sa0160 VSSA 2 2-4 1-2 2 0 (0) 
Sa0162 VSSA 1 1 1 2 0 (0) 
Sa0164 VSSA 1 2 2 2 0 (0) 
Sa0192 VSSA 1 2 2 2 0 (0) 
Sa0202 VSSA 1 2-4 2-4 2 0 (0) 
Sa0209 VSSA 1 2 2 2 0 (0) 
Sa0210 VSSA 1 2 2 2 0 (0) 
Sa0211 VSSA 1 2 2 2 0 (0) 
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Sa0212 VSSA 2 4 2 2 0 (0) 
Sa0214 VSSA 2 4 2 2 0 (0) 
Sa0228 VSSA 2 4 2 2 0 (0) 
Sa0265 VSSA 2 2-4 1-2 2 0 (0) 
Sa0283 VSSA 2 2 1 2 0 (0) 
Sa0294 VSSA 2 4-8 2-4 2 0 (0) 
Sa0308 VSSA 2 2 1 2 0 (0) 
Sa0322 VSSA 1 1 1 2 0 (0) 
Sa0323 VSSA 1-2 2 1-2 2 0 (0) 
Sa0324 VSSA 1 2 2 2 0 (0) 
Sa0325 VSSA 2 2 1 2 0 (0) 
Sa0329 VSSA 1 2 2 2 0 (0) 
Sa0330 VSSA 1 2 2 2 0 (0) 
Sa0331 VSSA 2 2 1 2 0 (0) 
Sa0332 VSSA 2 2-4 1-2 2 0 (0) 
Sa0363 VSSA 2 2 1 2 0 (0) 
Sa0375 VISA 4 8 2 4 0 (0) 
Sa0378 VISA 4-8 4-8 1 4 0 (0) 
Sa0484 VSSA 2 4-8 2-4 2 0 (0) 
1Abbreviations: VSSA, (vancomycin-susceptible S. aureus); VISA, (vancomycin-intermediate S. aureus); 
hVISA, (heterogenous vancomycin-intermediate S. aureus); MIC, (minimum inhibitory concentration); 
MBC, (Minimum bactericidal concentration); No., (Total number of tests performed); % (n), (percentage 
and number of tests positive) 
Tolerance was defined when the MIC:MBC ratio of an isolate was >32, or >16 if the vancomycin MIC was 
8 µg/mL 
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5.3 Effect of prolonged storage on tolerance 
An additional variable known to affect S. aureus tolerance is prolonged storage resulting in false negative 
results (Mayhall and Apollo 1980). This was seen in the supplied isolates from the US (data not shown). 
Therefore a series of persistent S. aureus strains isolated from sustained bacteraemic patients seen at RPAH 
(n=23) were prospectively tested for tolerance (Table 5.2). With the exception of Sa0747 exhibiting a MIC 
in the intermediate range (4µg/mL) in 1 of 2 tests, all strains yielded sensitive MIC results which replicated 
the MICs obtained from prior clinical testing. MBCs for these persistent strains were all within 1-3 dilutions 
of the organism’s MIC and the highest MBC:MIC ratio obtained among these strains was 8, and was only 
seen in Sa0751. Despite being tested prior to prolonged storage exposure, tolerance was not detected in any 
of these persistent isolates. 
 
Table 5.2 Tolerance testing – prospective isolates. 
Series Isolate 
Number 
Isolate Type MIC1 MBC1 MBC/MIC1 No. 1 Tolerant 
% (n) 1 
A Sa0744 Initial 1 2 2 2 0 (0) 
A Sa0745 Persistent 1 4 4 2 0 (0) 
A Sa0746 Persistent 1-2 1-2 1 2 0 (0) 
A Sa0747 Persistent 1-4 1-4 1-4 2 0 (0) 
A Sa0748 Persistent 1 1-2 1-2 2 0 (0) 
A Sa0749 Persistent 1 2 2 2 0 (0) 
A Sa0750 Persistent 1 1-2 1-2 2 0 (0) 
A Sa0751 Persistent 1 2-8 2-8 2 0 (0) 
B Sa0752 Initial 1 2 2 2 0 (0) 
B Sa0753 Persistent 1-2 2 1-2 2 0 (0) 
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B Sa0754 Persistent 1-2 2 1-2 2 0 (0) 
B Sa0755 Persistent 1 1-2 1-2 2 0 (0) 
B Sa0756 Persistent 1-2 2 1-2 2 0 (0) 
B Sa0757 Persistent 1-2 2 1-2 2 0 (0) 
C Sa0758 Initial 1 1-2 1-2 2 0 (0) 
C Sa0759 Persistent 1 2 2 2 0 (0) 
C Sa0760 Persistent 1-2 2-4 2 2 0 (0) 
C Sa0761 Persistent 1 1-2 1-2 2 0 (0) 
C Sa0762 Persistent 1 1-2 1-2 2 0 (0) 
C Sa0763 Persistent 1 1-2 1-2 2 0 (0) 
C Sa0764 Persistent 1 4 4 2 0 (0) 
C Sa0765 Persistent 1 2 2 2 0 (0) 
C Sa0766 Persistent 0.5-1 1-4 2-4 2 0 (0) 
1Abbreviations: MIC, (minimum inhibitory concentration); MBC, (Minimum bactericidal concentration); 
No., (Total number of tests performed); % (n), (percentage and number of tests positive)  
Tolerance was defined when the MIC:MBC ratio of an isolate was >32, or >16 if the vancomycin MIC was 
8 µg/mL 
 
5.4 Modification to CLSI method did not increase the detection of tolerance 
A study which reported a 70% hVISA and 100% VISA tolerance rate referred to using the CLSI method, 
but it was noted that the entire well volume (0.1mL) was transferred onto a HBA plate in the final 
inoculation step (Jones 2006), as opposed to the recommended transfer volume of 0.01mL (CLSI 1999).  
When using the CLSI method and transferring 0.01mL from the well contents onto HBA, the tolerance rate 
in this study for the Liverpool hVISA and VISA isolates did not resemble the tolerance rate described by 
Jones and colleagues (Table 5.3). Therefore, the same variation used by Jones and colleagues was adopted, 
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and the final transfer step was altered to 0.1mL (transfer of the entire well contents) onto a HBA plate. A 
series of predominantly hVISA and VISA strains were selected, with the aim of determining whether the 
volume used in the final step affects the ability to detect tolerance. 
Using a final transfer volume of 0.1mL in the MBC test, the MICs for each strain again matched their 
respective phenotypes, as the method described by Jones and colleagues does not affect the MIC test. MBCs 
for this isolate series were similarly within 1-2 dilutions of the organism MIC with the exception Sa0066, 
which displayed a MBC:MIC ratio of >32 and was classified tolerant in 1 of 2 tests (50% tolerance rate). 
All other isolates, which included 7 hVISA and 3 VISA strains were non tolerant. One of the VISA strains 
which was non-tolerant by this method was Mu50, which in comparison to using a final transfer volume of 
0.01mL in earlier testing, demonstrated tolerance in 1 out of 4 tests (25% tolerance rate).  
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Table 5.3 Tolerance testing Jones et al. method.  
Isolate 
Number 
Phenotype1 MIC1 MBC1 MBC/MIC
1 
No. 1 Tolerant 
% (n) 1 
29213 VSSA 2 2 1 1# 0 (0) 
Mu3 hVISA 2 4-8 2-4 2 0 (0) 
Mu50 VISA 8 16 2 2 0 (0) 
Sa0059 VISA 4 8 2 2 0 (0) 
Sa0061 hVISA 2-4 4 1-2 2 0 (0) 
Sa0062 hVISA 2 2-4 1-2 2 0 (0) 
Sa0063 hVISA 2 4 2 2 0 (0) 
Sa0064 hVISA 2 4 2 2 0 (0) 
Sa0065 hVISA 2 4 2 2 0 (0) 
Sa0066 VISA 4 8->128 2->32 2 50 (1) 
Sa0069 VSSA 1 2 1-2 2 0 (0) 
Sa0070 hVISA 2-4 4 1-2 2 0 (0) 
1Abbreviations: VSSA, (vancomycin-susceptible S. aureus); VISA, (vancomycin-intermediate S. aureus); 
hVISA, (heterogenous vancomycin-intermediate S. aureus); MIC, (minimum inhibitory concentration); 
MBC, (Minimum bactericidal concentration); No., (Total number of tests performed); % (n), (percentage 
and number of tests positive)  
Tolerance was defined when the MIC:MBC ratio of an isolate was >32, or >16 if the vancomycin MIC was 
8 µg/mL 
#Single test for strain 29213 excluded as a result of contamination.  
 
 60 
 
5.5 Choice of culture media used prior to testing may affect tolerance detection 
MBC testing was performed on reported tolerant strains Sa0793 (220-post) and Sa0794 (225-post) supplied 
by the United States, which had in-vitro vancomycin exposure prior to receipt (Rose, Fallon et al. 2012). 
This study confirmed tolerance in these strains in a time-kill test when using MDK90 of 6 h as the criteria 
for tolerance.  
MBC tests were performed in tandem on two sets of isolates from the same parent strain: One performed 
on isolates grown on Mueller-Hinton agar containing 2 µg/mL vancomycin (MHAV), and another 
performed on a fresh overnight HBA subculture from the colonies grown on MHAV. These strains were 
tested using the CLSI method with the recommended 0.01mL transfer volume. 
The MICs for Sa0793 and Sa0794 were consistently 2 µg/mL, irrespective of the solid media used prior to 
testing (Table 5.4). The MICs obtained for Sa0793 and Sa0794 classified them as VSSA strains and did not 
align with the obtained PAP results which classified the strains as VISA.  
MBCs for both Sa0793 and Sa0794 were >128 µg/mL when tested directly from MHAV and the MBC:MIC 
ratio for both isolates was >64. Sa0793 was classified tolerant in 2 of 2 tests (100% tolerance rate) and 
Sa0794 tolerant in 1 of 2 tests (50% tolerance rate).  
Despite being cultured onto HBA from a MHAV plate, MBCs were consistently lower (1-3 dilutions from 
the organism MIC) when the same strains were tested directly from a fresh HBA subculture plate, and in 
this tests these strains were consequently classified as non-tolerant.  
  
 61 
 
Table 5.4 Tolerance results for known tolerant strains.  
Isolate 
Number 
Pre-test 
culture media1 
MIC1 MBC1 MBC/MIC1 No. 1 Tolerant 
% (n) 1 
Sa0793 HBA 2 8-16 4-8 2 0 (0) 
Sa0793 MHAV 2 >128 >64 2 100 (2) 
Sa0794 HBA 2 4 2 2 0 (0) 
Sa0794 MHAV 2 4->128 2->64 2 50 (1) 
1Abbreviations: HBA (horse blood agar); MHAV, (Mueller-Hinton agar containing 2 µg/mL vancomycin); 
MIC, (minimum inhibitory concentration); MBC, (Minimum bactericidal concentration); No., (Total 
number of tests performed); % (n), (percentage and number of tests positive)  
Tolerance was defined when the MIC:MBC ratio of an isolate was >32, or >16 if the vancomycin MIC was 
8 µg/mL 
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Chapter 6 
Results 
Modified method – gradual vancomycin exposure to the organism’s MIC 
 
6.1 Introduction 
Prior to being used in this study, tolerant strains 220 and 225 were non-tolerant upon retesting when 
retrieved from storage (data not shown – performed by the University of Wisconsin), and tolerance was 
detected when these strains were exposed to sub-lethal concentrations of vancomycin. Furthermore in this 
study, tolerance was detected in these strains when performing MBC testing from colonies grown in 
vancomycin-containing solid media, and tolerance was not detected when MBC testing was performed on 
the same colonies obtained from solid media that did not contain vancomycin.  
To explore the effect of vancomycin-containing culture media has on tolerance, a selection of 2 VSSA, 6 
hVISA and 4 VISA strains were passaged in increasing concentrations of vancomycin until the 
concentration reached the organism’s vancomycin MIC (obtained from previous MIC/MBC results in 
Chapter 5), followed by MBC testing according to CLSI guidelines. VSSA strains ATCC 29213 and clinical 
strain Sa0484 acted as a negative tolerant controls. The MICs obtained (in µg/mL) which were used as the 
final vancomycin concentration were as follows: 29213: 2; Mu3: 2, Mu50: 8, Sa0044: 4, Sa0059: 4, Sa0061: 
2, Sa0063: 2, Sa0065: 2, Sa0066: 4, Sa0070: 2, Sa0484: 2, Sa0793: 2.  
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6.2 Tolerance detected, but elevated MICs also seen 
Elevated MICs were seen in VSSA strains 29213 and Sa0484 which both displayed MICs of 4 µg/mL 
(Table 6.1). The raised MIC indicates intermediate resistance to vancomycin and according to CLSI 
breakpoints, these strains would be classified as VISA. The hVISA strain Sa0065 also displayed an elevated 
MIC of 4 µg/mL, which would classify this strain as a VISA.  
Tolerance was detected in all VISA strains (100%) as the MBCs obtained for these strains ranged from 64-
128 µg/mL; facilitating a MBC:MIC ratio of 16->32. 4 out of 6 hVISA strains (66.67%) were tolerant, 
however Sa0044 and Sa0063 displayed tolerance in 1 of 2 tests. All tolerant hVISA strains had MBCs of 
>128 µg/mL and MBC:MIC ratios of >32. 
Tolerance was not detected in either VSSA strain, however the MBC for 29213 was raised in comparison 
to the result obtained without pre-exposure to vancomycin (MBC=16 µg/mL when passaged in 2 µg/mL 
vancomycin; MBC=2 µg/mL when using CLSI method alone). The MBC:MIC ratio for 29213 was also 
raised when pre-passaged in vancomycin (MBC:MIC=4), though this did not classify the strain as being 
tolerant. 
With the addition of a vancomycin pre-exposure step to the organism’s MIC, results resembled the reported 
tolerance rates seen in another study (tolerance rate: 70% hVISA; 100% VISA) (Jones 2006).  
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Table 6.1 Tolerance results for isolates passaged in increasing vancomycin concentrations.  
Isolate 
Number 
Phenotype1 MIC1 MBC1 MBC/MIC1 No. 1 Tolerant 
% (n) 1 
29213 VSSA 4 16 4 2 0 (0) 
Mu3 hVISA 2 4 2 2 0 (0) 
Mu50 VISA 8 >128 >32 2 100 (2) 
Sa0044 hVISA 4 8->128 2->32 2 50 (1) 
Sa0059 VISA 4 8-64 2-16 2 0 (0) 
Sa0061 hVISA 1 2 2 2 0 (0) 
Sa0063 hVISA 2 4-->128 2->32 2 50 (1) 
Sa0065 hVISA 4 >128 >32 2 100 (2) 
Sa0066 VISA 4 >128 >32 2 100 (2) 
Sa0070 hVISA 4 >128 >32 2 100 (2) 
Sa0484 VSSA 4 8 2 2 0 (0) 
Sa0793 VISA 4 >128 >32 2 100 (2) 
1Abbreviations: VSSA, (vancomycin-susceptible S. aureus); VISA, (vancomycin-intermediate S. aureus); 
hVISA, (heterogenous vancomycin-intermediate S. aureus); MIC, (minimum inhibitory concentration); 
MBC, (Minimum bactericidal concentration); No., (Total number of tests performed); % (n), (percentage 
and number of tests positive)  
Tolerance was defined when the MIC:MBC ratio of an isolate was >32, or >16 if the vancomycin MIC was 
8 µg/mL 
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Chapter 7 
Results 
Modified method – 0.5x vancomycin MIC 
 
7.1 Introduction 
As a result of the increased MICs seen in some VSSA and hVISA strains when pre-exposed to vancomycin 
to the point of an organism’s MIC, a secondary modification was investigated to see whether tolerance is 
still detected when a lower concentration of vancomycin is used during the pre-testing step, without altering 
the MIC result. Prior to testing, a selection of strains were incubated in BHI containing vancomycin at half 
the organisms measured MIC. The vancomycin concentration used (at 0.5X MIC) based on previous MICs 
obtained (in µg/mL) were as follows: 29213: 1, Mu50: 4, Sa0066: 2, Sa0793: 1. Strains were also pre-
enriched in BHI without the added vancomycin prior to testing, which acted as a neutral comparator. 
 
7.2 MIC/MBC data 
Exposure to 0.5X vancomycin MIC prior to testing did not affect the organism MIC, as the MICs obtained 
for all strains matched their respective phenotypes (Table 7.1). The MICs obtained for the isolates pre-
exposed to vancomycin were comparable to MICs obtained from isolates that underwent pre-enrichment in 
BHI without vancomycin. Similar to previous results seen in this study, Sa0793 had an MIC of 2 µg/mL 
despite being classified as a VISA by PAP. This was also seen in Sa0066, also a VISA strain, which had a 
MIC of 2 µg/mL.  
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Strains 29213 and Mu3 were non-tolerant irrespective of the pre-testing culture media used. MBC results 
across the two methods were also comparable, though tolerance was seen more readily in isolates when 
pre-exposed to vancomycin. Tolerance was detected in 4/4 (100%) VISA strains when pre-exposed to 
vancomycin, compared to 3/4 (75%) tolerant VISA strains when pre-enriched in BHI without vancomycin.   
Sa0793 was tolerant in 2 of 2 tests (100% tolerance rate) when pre-exposed to vancomycin, compared to 
tolerance seen in 2 out of 4 tests (50% tolerance rate) when pre-enriched in BHI without vancomycin. 
Tolerance was seen in 1 of 2 tests for Sa0794 (50% tolerance rate) when pre-exposed to vancomycin, but 
as a result of a lower MBC:MIC ratio seen in the same strain when pre-exposed in BHI without vancomycin 
(range: 4-8), this organism was non-tolerant using the latter pre-exposure step. 
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Table 7.1 Tolerance results for isolates grown with and without vancomycin at 0.5x MIC.  
Isolate 
Number 
Phenotype 
Exposure to vancomycin at 0.5x MIC Pre-enrichment in BHI 
MIC MBC MBC / 
MIC 
No.  Tolerant 
% (n) 
MIC MBC MBC / 
MIC 
No. Tolerant 
% (n) 
29213 VSSA 1-2 1-2 1-2 4 0 (0) 1 1-2 1-2 4 0 (0) 
Mu3 hVISA 2 4 2 2 0 (0) 2 4 2 2 0 (0) 
Mu50 VISA 8 >128 >16 4 100 (4) 8 >128 >16 4 100 (4) 
Sa0066 VISA 2-8 >128 >32->64 4 100 (4) 2-4 >128 >32->64 4 100 (4) 
Sa0793 VISA 2 >128 >64 2# 100 (2) 2-4 8->128 >64 4 50 (2) 
Sa0794 VISA 4 8->128 8->32 2 50 (1) 4 4-8 1-2 2 0 (0) 
Abbreviations: BHI, (brain heart infusion); VSSA, (vancomycin-susceptible S. aureus); VISA, 
(vancomycin-intermediate S. aureus); hVISA, (heterogenous vancomycin-intermediate S. aureus); MIC, 
(minimum inhibitory concentration); MBC, (Minimum bactericidal concentration); No., (Total number of 
tests performed); % (n), (percentage and number of tests positive)  
Tolerance was defined when the MIC:MBC ratio of an isolate was >32, or >16 if the vancomycin MIC was 
8 µg/mL 
#One test set for strain Sa0793 excluded as a result of contamination.  
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Chapter 8 
Results 
Modified method – pre-enrichment step 
 
8.1 Introduction 
BHI was an enrichment medium used in this study for all in vitro vancomycin pre-exposure steps, and BHI 
was used by the University of Wisconsin when conducting in vitro vancomycin passages in an attempt to 
revive the tolerance phenotype in strains 220 and 225. Although it was used as a neutral comparator in the 
vancomycin pre-exposure method described in the Chapter 7, results in Table 7.1 showed an increase in the 
reported tolerance rate in Mu50 and Sa0066 when using pre-enrichment prior to testing (100%; both 
isolates), when compared to results seen in Tables 5.1 and 5.3 when tested earlier in this study (16.67% and 
25% respectively).  
Therefore this study investigated another experimental method where isolates underwent a pre-enrichment 
step in BHI prior to MIC/MBC testing and were tested alongside the CLSI recommended method. Isolates 
chosen for this study consisted of 4 hVISA, 5 VISA, and 7 VSSA strains which acted as negative controls.  
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8.2 MIC/MBC data 
Pre-enrichment did not affect the MIC for any isolate: the MIC obtained for all isolates were consistent 
across both methods and matched the organism’s respective phenotype.  
Tolerance was not detected in any VSSA and hVISA strain using either method, however tolerance was 
seen in Mu50, Sa0066, Sa0793 and Sa0794 (all VISA isolates), but there were variations in the number of 
reported tolerant strains and tolerance rate between both methods (Table 8.1). Mu50 was tolerant only when 
pre-enrichment was used prior to testing (3 of 10 tests; 30% tolerance rate), and Sa0066 was tolerant in 8 
of 8 tests (100% tolerance rate) in the pre-enrichment method, compared to 6 of 8 tests (75% tolerance rate) 
using the CLSI method. Tolerance was detected in Sa0793 in 1 of 10 tests (10% tolerance rate) in the pre-
enrichment method compared to 3 of 10 tests (30% tolerance rate) when using the CLSI method, and 
tolerance was only detected in Sa0794 in 2 of 10 tests (20% tolerance rate) when using the CLSI method. 
As the MBC:MIC ratio for Sa0794 was between 1-2 when using the pre-enrichment method, this classified 
the isolate as non-tolerant. 
Table 8.1 Tolerance results for isolates with and without enrichment.  
Isolate 
Number 
Phenotype 
Pre-enrichment in BHI CLSI method (No enrichment) 
MIC MBC MBC 
/ MIC 
No.  Tolerant 
% (n) 
MIC MBC MBC / 
MIC 
No. Tolerant 
% (n) 
29213 VSSA 1 1-2 1-2 10 0 (0) 1 1-2 1-2 10 0 (0) 
Mu3 hVISA 2 2-4 2 10 0 (0) 1-2 4 2-4 10 0 (0) 
Mu50 VISA 4-8 4->128 1->32 10 30 (3) 4-8 4-32 1-4 10 0 (0) 
Sa0048 VSSA 2 2 1 2 0 (0) 2 2 1 2 0 (0) 
Sa0050 hVISA 2 4 2 2 0 (0) 2 4 2 2 0 (0) 
Sa0055 VSSA 1 1-2 1-2 2 0 (0) 1 2 2 2 0 (0) 
Sa0056 hVISA 2 4 2 2 0 (0) 4 4 1 2 0 (0) 
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Sa0057 VSSA 1 2 2 2 0 (0) 1 2 2 2 0 (0) 
Sa0058 hVISA 2 2 1 2 0 (0) 2 2 1 2 0 (0) 
Sa0066 VISA 2-4 >128 >32 8 100 (8) 2-4 4->128 1->32 8 75 (6) 
Sa0375 VISA 4 4-16 1-4 2 0 (0) 4 4-32 1-8 2 0 (0) 
Sa0484 VSSA 1 1-2 1-2 2 0 (0) 1 2 2 2 0 (0) 
Sa0793 VISA 4 4->128 1->32 10 10 (1) 4 4->128 1->32 10 30 (3) 
Sa0794 VISA 2-4 4 1-2 8 0 (0) 2-4 2->128 1->32 10 20 (2) 
Sa0795 VSSA 1 1-2 1-2 2 0 (0) 2 2 1 2 0 (0) 
Sa0796 VSSA 2 2 1 2 0 (0) 1 1 1 2 0 (0) 
Abbreviations: BHI, (brain heart infusion); VSSA, (vancomycin-susceptible S. aureus); VISA, 
(vancomycin-intermediate S. aureus); hVISA, (heterogenous vancomycin-intermediate S. aureus); MIC, 
(minimum inhibitory concentration); MBC, (Minimum bactericidal concentration); No., (Total number of 
tests performed); % (n), (percentage and number of tests positive)  
Tolerance was defined when the MIC:MBC ratio of an isolate was >32, or >16 if the vancomycin MIC was 
8 µg/mL  
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Chapter 9 
Results 
Comparing tolerance results across the four methods used 
 
9.1 Introduction 
Tolerance results for isolates 29213 (negative control), Mu3 (hVISA control), Mu50 (VISA control), 
Sa0066 (a known clinical VISA strain), and Sa0793 and Sa0794 (known tolerant strains; grown in the 
presence of 2 µg/mL vancomycin) across the four methods used in this study were collated and are 
represented in Table 9.1. The compared methods included: existing methodology recommended by the 
CLSI guidelines, vancomycin passage to the organism’s MIC, vancomycin at 0.5X the organism’s MIC, 
and pre-enrichment in BHI. 
The technical factors described with MBC testing were considered across all four methods: while the 
inoculum size is recognised as an important factor for MBC testing, isolates grown to logarithmic phase (3 
h) were measured against a known MacFarland reference standard prior to inoculation in the microtitre tray. 
Subsequent bacterial counts were verified the follow day and were within the acceptable range of 1-9 x 105 
cfu/mL. A 0.01 mL volume was subcultured from clear MIC wells and plated on HBA and antibiotic 
carryover was not found to be a problem. Though the paradoxical effect has been described in S. aureus 
and MBC testing, the paradoxical effect was not seen in this study, even when strains were pre-exposed to 
vancomycin prior to testing. 
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9.2 Tolerance results 
The negative quality control strain ATCC 29213 was non-tolerant from a total of 35 MBC tests across 4 
variations in testing methodology, and Mu3 was also non-tolerant across all methods from a total of 32 
MBC tests, despite being classified as an hVISA strain.  
Tolerance was only detected in VISA strains and was readily detected if the isolates were pre-exposed to 
vancomycin prior to testing, regardless of whether it was achieved via serial vancomycin passage or 
exposure at half the organism’s vancomycin MIC. When pre-exposed to any concentration of vancomycin, 
the tolerance rate for Mu50, Sa0066 and Sa0793 was 100%, and the tolerance rate for Sa0794 was 50%.   
The pre-enrichment method detected a lower tolerance rate when compared to the vancomycin pre-exposure 
method, but was slightly higher overall when compared to the CLSI method. The tolerance rate using the 
pre-enrichment method for Mu50 was 50%, Sa0066: 100%, and Sa0793: 21%, compared to the tolerance 
rates seen in the CLSI method which were 17%, 70% and 25% respectively.  
The CLSI method detected tolerance in Sa0794 (tolerance rate: 17%). In comparison, the enrichment 
method was the only method which failed to detect tolerance in this strain.  
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Table 9.1 Comparability of tolerance results across four methods.  
Isolate 
Number 
Phenotype1 
CLSI method 
(HBA) 
Vancomycin 
Passage 
0.5x 
Vancomycin 
MIC 
Enrichment 
method (BHI) 
No. 
Tolerant 
% (n) 1 
No. 
Tolerant 
% (n) 1 
No. 
Tolerant 
% (n) 1 
No. 
Tolerant 
% (n) 1 
29213 VSSA 15 0 (0) 2 0 (0) 4 0 (0) 14 0 (0) 
Mu3 hVISA 16 0 (0) 2 0 (0) 2 0 (0) 12 0 (0) 
Mu50 VISA 6 17 (1) 2 100 (2) 4 100 (4) 14 50 (7) 
Sa0066 VISA 10 70 (7) 2 100 (2) 4 100 (4) 12 100 (12) 
Sa0793 VISA 12 25 (3) 4* 100 (4*) 2 100 (2) 14 21 (3) 
Sa0794 VISA 12 17 (2) 2* 50 (1*) 2 50 (1) 10 0 (0) 
Abbreviations: BHI, (brain heart infusion); VSSA, (vancomycin-susceptible S. aureus); VISA, 
(vancomycin-intermediate S. aureus); hVISA, (heterogenous vancomycin-intermediate S. aureus); MIC, 
(minimum inhibitory concentration); MBC, (Minimum bactericidal concentration); No., (Total number of 
tests performed); % (n), (percentage and number of tests positive)  
Tolerance was defined when the MIC:MBC ratio of an isolate was >32, or >16 if the vancomycin MIC 
was 8 µg/mL 
*Includes results obtained when tested directly from a MHA plate containing 2 µg/mL vancomycin. 
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Chapter 10 
Discussion 
10.1 Introduction 
Variations in MBC testing has led to uncertainty in the results and has questioned the clinical significance 
of tolerance. Therefore, this study examined the methodology associated with MBC and tolerance testing.  
A high prevalence rate of tolerance has been previously reported in hVISA and VISA strains (Jones 2006, 
Cazares-Dominguez, Cruz-Cordova et al. 2015), therefore this study examined tolerance testing on an S. 
aureus culture library consisting of a number of hVISA and VISA strains, with the expectation that this 
study will yield similar tolerance rates. 
There are ongoing variations in MBC testing methodology post issuance of CLSI guidelines (Table 10.1), 
therefore the overall aim of this study was to determine how method variations affect the ability to detect 
vancomycin tolerance in S. aureus.  
 
10.2 PAP of control strains 
Population-analysis profiling-area under the curve (PAP-AUC) is not a requirement for tolerance testing, 
but provides a definitive phenotype profile for S. aureus strains, particularly when determining whether a 
strain is an hVISA.  Previous PAP-AUC tests (performed prior to this study on isolates from the ARMEG 
culture collection library) were useful in identifying hVISA and VISA isolates that were suited for this 
study, as they are associated with sustained bacteraemia (van Hal, Jensen et al. 2012) and vancomycin 
tolerance (Jones 2006, Cazares-Dominguez, Cruz-Cordova et al. 2015). 
PAP-AUC was also used to determine the phenotype for each ATCC control strain that were used as 
positive and negative controls for all MBC and time-kill tests. All ATCC strains generated PAP-AUC ratios 
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which confirmed their respective phenotypes and PAP results aligned with what is seen in the literature 
(Perazzi, Bello et al. 2011).  
PAP-AUC was used to determine the phenotype for reported tolerant strains 220 and 225 and results 
demonstrated a difference in phenotype depending on whether the strains were subjected to an in vitro 
induced tolerance step via serial vancomycin passage. PAP-AUC classified strains Sa0795 and Sa0796 as 
VSSA, yet when undergoing vancomycin passage, strains Sa0793 and Sa0794 were classified as VISA. 
This was further emphasised in the MICs obtained for each strain: MIC for strains Sa0795 and Sa0796 
ranged from 1-2 µg/mL, and the vancomycin passaged strains Sa0793 and Sa0794 demonstrated MICs up 
to 4 µg/mL, classifying them closer to the VISA phenotype. This suggests in vitro serial passages in 
vancomycin may facilitate a change in phenotype, most likely as a result of antibiotic pressure.  
 
10.3 Time-kills 
Tolerance results varied among the hVISA and VISA strains depending on the definition used in time-kill 
assays. The CLSI definition of a <3-log10 reduction of the bacterial count after 24 h classified the VISA 
isolate Sa0066 as tolerant, but failed to classify Mu3 (hVISA), Mu50 (VISA), and the two reported tolerant 
strains that underwent vancomycin passage Sa0793 and Sa0794 (which were determined to be VISA by 
PAP-AUC) as tolerant, showing variability at this time point for detecting tolerance in VISA strains. In 
contrast, using the MDK90 of 6 h classified all hVISA and VISA strains as tolerant, suggesting that this a 
more robust criteria for categorising tolerance. Mu3 was noted as having survivors close to the cut-off 
(10.8% colonies at 6 h), though this is not surprising considering that the majority of an hVISA population 
displays susceptible MICs and only small a sub-population possess intermediate resistance to vancomycin 
(van Hal and Paterson 2011).  
Comparing the time-kill data in quality control strains 29213, Mu3 and Mu50 demonstrated consistently 
lower viable counts if the time-kill assay was plated on LBA compared to being plated on HBA. When 
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plated on LBA and using the CLSI definition, Mu3 and Mu50 were classified as non-tolerant. This 
contrasted the tolerance observed when plated on HBA, suggesting that LBA is not nutritious-rich like 
HBA, and supports the CLSI recommendation of using HBA as solid media. Surprisingly, the number of 
remaining colonies on HBA at 24 h for Mu3 exceeded Mu50 (0.22% versus 0.13% respectively). One 
would expect a higher percentage of remaining colonies in a VISA isolate compared to a hVISA, given the 
higher MICs associated with VISA strains.  
Despite the lower counts observed on LBA, using the MDK90 of 6 h definition provided better consistency 
across both plate media used and classified Mu3 and Mu50 as tolerant, which also favours using MDK90 of 
6 h for the classification of tolerance in a time-kill assay. 
The variation in tolerance classification when using the CLSI definition illustrates why this time point is 
considered too arbitrary. Using the CLSI definition, Mu3 and Mu50 were classified as non-tolerant in two 
time-kill assays (Figure 4.2 and 4.3 – LBA) and tolerant in another (Figure 4.3 – HBA), suggesting that the 
24 h time point does not consistently detect tolerance in documented tolerant strains. In contrast using the 
MDK90 of 6 h classified every hVISA and VISA strain as tolerant, provided they were plated on HBA. 
Therefore the results from this study suggest that bactericidal activity is better represented within the first 
8 h of a time-kill curve, and strongly suggests that using the criteria of MDK90 of 6 h is more suited as the 
breakpoint for defining tolerance.  
Antibiotic streak controls were performed for all strains with each time-kill assay, and whilst antibiotic 
carry-over has been previously described in S. aureus, this was found not to be a problem in this study.  
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10.4 Tolerance testing: MBC method 
Using current CLSI guidelines, MBC testing on a large pool of hVISA and VISA strains in addition to S. 
aureus strains isolated from sustained bacteraemia episodes failed to readily produce tolerant strains: only 
2 out of 65 isolates were tolerant, and tolerance was unable to be consistently demonstrated in duplicate 
testing. These results are surprising considering the reported rate of tolerance seen in hVISA and VISA 
strains in one large study were 70% for hVISA and 100% for VISA isolates (Jones 2006), and another study 
classified 41.66% of their tolerant strains as hVISA by PAP-AUC (Cazares-Dominguez, Cruz-Cordova et 
al. 2015). When adopting the same pipetting method as described by Jones and colleagues, the results from 
this study again failed to replicate the same tolerance rates, and tolerance results were similar to when 
0.01mL of the well contents were transferred: 1 of 11 isolates were tolerant, and tolerance was not 
consistently demonstrated. 
Tolerance is thought to be unstable and may diminish upon prolonged storage (Sabath, Wheeler et al. 1977, 
Mayhall and Apollo 1980) and could explain the negative results seen in this study when using the CLSI 
method, as all hVISA/VISA isolates used in this study have been stored at -80ºC for periods >10 years.  
Storage is also presumed to be a factor for the negative tolerance results seen in the tolerant strains from 
the US (which required in vitro vancomycin passage in order to resuscitate the tolerance phenotype). Ideally 
isolates would be tested in real time, but as the prevalence of hVISA and VISA strains is low (van Hal, 
Jensen et al. 2012), it would be unachievable to perform MBC testing in real-time on suspected hVISA 
isolates (particularly when these strains can only be definitively identified by PAP-AUC; a test which is 
not routinely performed by clinical laboratories). As VISA and hVISA strains are associated with sustained 
bacteraemia (van Hal, Jensen et al. 2012), this study carried out prospective MBC testing on a series of S. 
aureus strains obtained from 3 patients with sustained bacteraemia. Prospective MBC testing using the 
CLSI method did not detect tolerance in these strains, which raises further uncertainty with the sensitivity 
of MBC testing using existing methodology. 
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This study initially used a BHI pre-enrichment step as a comparator in the vancomycin pre-exposure 
method, and noted an increase in the reported tolerance rates when compared to results seen using the CLSI 
method. It was also noted that the additional pre-enrichment step did not adversely affect any MIC results. 
An overall comparison of both methods suggests increased sensitivity in tolerance detection when using a 
pre-enrichment step prior to MBC testing using CLSI guidelines; strains Mu50 and Sa0066 showed marked 
increases reported tolerance rates and Sa0793 demonstrated comparable rates across both methods. 
Surprisingly, tolerance was detected in Sa0794 only when using the CLSI method, however this was not 
readily reproduced, suggesting tolerance is an unstable phenotype even if an enrichment step is used. While 
the results seen in strain Sa0794 demonstrate variability in the expression of tolerance, the overall results 
suggest BHI may provide additional nutrients and enhances tolerance detection by supporting an organism’s 
ability to express the tolerance phenotype, particularly if the organism was frozen prior to testing. 
Reported tolerant strains 220 and 225 supplied from the US were non-tolerant upon repeat testing after 
subculture from prolonged storage at -80ºC (performed prior to receipt), and tolerance was detected once 
the strains were exposed to vancomycin in vitro via daily passage (also performed prior to receipt). In this 
study MBC testing on these isolates demonstrated variability in the expression of tolerance: tolerance was 
better detected when MBC testing was performed on isolates taken directly from vancomycin-containing 
agar, and tolerance was not detected when these isolates were subsequently subcultured onto HBA prior to 
MBC testing. 
Tolerance was readily detected in hVISA and VISA isolates (including one of the supplied tolerant strains) 
when pre-exposed to vancomycin to the point of the organism’s MIC prior to MBC testing, however 
exposure to vancomycin at this concentration elevated the MIC for 3 strains. The MICs obtained for ATCC 
29213 and Sa0484 (4 and 8µg/mL respectively) is concerning as both strains would be classified as VISA 
isolates and furthermore, the MIC for 29213 does not correlate with the MICs established by the ATCC. 
This suggests vancomycin passage to the organism’s MIC may generate a false-positive VISA phenotype 
in a MIC test in isolates that would normally test as vancomycin-susceptible. In a clinical setting this may 
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discourage the use of vancomycin as therapy and would instead encourage alternative and or additional 
therapies for successful treatment. Elevated MICs were not seen if the vancomycin passage was limited to 
0.5X the organism’s MIC, and yielded tolerance rates similar to when the isolates were pre-exposed to 1X 
their vancomycin MIC (tolerance was detected in all VISA strains).  
The reported tolerant strains that were used for this study required vancomycin passage to revive the 
tolerance phenotype. Similarly, tolerance has also been previously shown to be gained or lost in vitro during 
repeated subculture in the presence or absence of antibiotic (Voorn, Thompson et al. 1994). Therefore it 
can be hypothesised that tolerance may emerge during clinical therapy (in this case vancomycin therapy) 
and may be lost in the clinical laboratory upon subculture of the isolate onto non-selective media, resulting 
from the absence of vancomycin in the media (May, Shannon et al. 1998). The results in this study have 
demonstrated that tolerance was lost and gained in strains 220 and 225 and was dependant on pre-testing 
conditions and culture media used prior to MBC testing. Considering that the vancomycin passage step was 
performed in BHI (which demonstrated the highest yield in tolerance rates for our hVISA/VISA isolates), 
pre-exposure to vancomycin in BHI may be the optimal growth condition for an organism to express the 
tolerance phenotype. 
MBC testing failed to detect tolerance in any hVISA strain when using the CLSI or pre-enrichment 
methods. Considering that the CLSI recommended breakpoint for tolerance in a time-kill failed to 
consistently demonstrate tolerance in Mu3, this could also explain the negative results seen in MBC testing 
as the 24 h analysis time-point is also used in MBC testing. Additionally when using the MDK90 of 6 h as 
a criteria for tolerance, Mu3 was close to the tolerance cut-off (10.8-27.5% remaining colonies) which may 
also explain the negative results seen in the MBC test. Tolerance, however, was readily detected in several 
hVISA strains if they were pre-exposed to vancomycin prior to MBC testing. This is likely due to a selection 
for the reduced-susceptible sub-population, which is a direct consequence of pre-exposure in vancomycin 
during the passage step.  
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Overall, the results of this study demonstrate that the choice of culture media used prior to MBC testing 
affects the ability to detect tolerance. As laboratories still use variations in methodology for MBC testing 
(Table 10.1), this study may explain the variability seen in the number of reported tolerance rates. With 
respect to MBC testing, a pre-exposure step in vancomycin may be the best approach for detecting tolerance 
and when pre-exposed to vancomycin, the tolerance rate seen in hVISA and VISA strains closely aligned 
with the tolerance detected via time-kill assays when the MDK90 of 6 h was used as the breakpoint for 
tolerance. In order to avoid the raised MICs seen as demonstrated in the ATCC 29213 vancomycin 
susceptible strain, it would be recommended to avoid using vancomycin concentrations at the organism’s 
MIC, and instead favour concentrations at half the measured MIC. Pre-exposure to vancomycin did not 
induce tolerance in the non-tolerant ATCC 29213 strain and was also not seen in any persistent VSSA 
strains, which suggests that tolerance is not artificially induced in vitro in non-tolerant strains, moreover an 
organism must intrinsically possess the tolerance phenotype in order to express tolerance.  
 
10.6 Conclusion 
The variability of MBC test procedures coupled with the various definitions of tolerance were initially 
significant factors contributing to the different proportion of strains reported as antibiotic tolerant (Sherris 
1986). To overcome this deficiency, the CLSI issued testing guidelines in 1999, which have not been 
revised since. Despite these recommendations, laboratories testing for tolerance since then, have instituted 
modifications to the method (Table 10.1). These include the use of different solid media and the amount of 
volume used to determine the MBC. Though the results from this study have demonstrated overall lower 
counts in a time-kill when organisms are plated on LBA compared to HBA, the effect of these media 
changes in these other studies are still largely unknown as the recommended testing method is not included 
as a comparator. Unlike media modifications, volume changes are known to play a significant role in the 
detection of tolerance due to antibiotic carry-over, especially when volumes >0.01 mL are used compared 
to the recommended 0.01 mL (Pearson, Steigbigel et al. 1980). Vancomycin is described as a slowly 
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bactericidal antibiotic, further complicating the analysis and interpretation of tolerance with this antibiotic 
(Kollef 2007). Taken together, these differences may explain the large variability (between 4 and 50%) in 
the prevalence of tolerant isolates detected (Reis, Eisencraft et al. 1995, Honda, Doern et al. 2011, Pasticci, 
Moretti et al. 2011, Rose, Fallon et al. 2012, Gonzalez, Sevillano et al. 2013). An additional variable known 
to affect S. aureus tolerance is prolonged storage resulting in false negative results (Mayhall and Apollo 
1980). Although this was evident in the reported tolerant strains which were provided for this study (isolates 
220 and 225), prospective MBC testing using the CLSI guidelines on the three patient series S. aureus 
strains isolated from sustained bacteraemia episodes failed to identify tolerance, despite not having stored 
these strains at -80ºC prior to testing. 
This study confirms the need for ongoing standardization of methodology and definitions of tolerance, and 
that the classification of tolerance by time kill studies may be the optimal method. Furthermore, it could be 
argued that the MDK90 at 6 h is probably the best cut-off to use especially due to the large variability that 
exists in bacterial growth, antibiotic concentration and culture media after 6 h (Kaye 1980). This is 
highlighted when considering the results obtained for the hVISA and VISA strains, which are documented 
tolerant isolates, and had demonstrated tolerance in MBC tests when pre-exposed to vancomycin. In 
addition, if MIC/MBC testing is to be performed, an enrichment step supplemented with a sub-lethal 
concentration of vancomycin is required prior to testing.   
Irrespective, there are numerous obstacles before further methodological refinement is undertaken. First 
and foremost is the establishment of a “gold standard” for tolerance. Unfortunately, the genetic basis for 
tolerance remains to be determined, however, this study suggests that tolerance may be a surrogate for 
reduced glycopeptide susceptibility as tolerance could not be confirmed in any VSSA isolate using any 
methods, even when pre-exposed to vancomycin. Optimal timing of testing should be established as should 
result thresholds for defining tolerance. While the vancomycin MIC breakpoints have been revised in the 
last decade, there has been no change in defining tolerance despite reduced vancomycin activity and 
sustained infections being recognized as a major challenge in the treatment of invasive MRSA infections.  
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A recent review of tolerance suggested similar standardization and has proposed determining the MDK in 
a time-kill, to distinguish between tolerance, persistence, and non-tolerance (Brauner, Fridman et al. 2016). 
These principals were employed in this study and would be recommended for any future tolerance 
methodology recommendations. However, this concept is subject to variations in methodology and the same 
inherent flaws.  
Without better understanding of clinical and microbiologic features of tolerance and optimization of method 
development resulting in demonstrated consistency, it will remain a significant challenge to identify the 
clinical implications of tolerance and establish tolerance testing in diagnostic laboratories to improve 
antimicrobial selection.  
In conclusion, current guidelines and methods used for determining antibiotic tolerance are in urgent need 
of review. The results from this study strongly recommends using the MDK90 of 6 h in a time-kill assay 
over the CLSI recommendation for the classification of tolerance. The results from this study also 
demonstrate increased sensitivity in detecting vancomycin tolerance in staphylococci when pre-exposing 
isolates in vancomycin-containing enrichment media. This pilot study proposes a methodological 
enhancement to tolerance testing which can provide the framework for a large-scale future study, which 
would be meaningful in determining the clinical impact of vancomycin tolerance on patient outcomes with 
invasive MRSA infections.  
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Table 10.1 Tolerance methodologies implemented post 1999. 
Solid media used 
for colony counts 
Volume used 
to plate on 
solid media 
(mL) 
Comments Reference 
TSA blood agar 0.02  (Honda, Doern et al. 2011) 
Horse blood agar 0.01  (May, Shannon et al. 1998) 
Unknown media Entire well 
volume 
73.9% hVISA and 100% 
VISA isolates were found 
tolerant. 
(Jones 2006) 
Sheep blood agar 0.025  (Sakoulas, Moise-Broder et 
al. 2004) 
Tryptic soy agar 0.02  (Aeschlimann, Hershberger 
et al. 1999) 
Muller-hinton agar 0.05  (Pasticci, Moretti et al. 
2011) 
Brain heart infusion 
agar 
Unknown  (Rose, Leonard et al. 2008) 
Tryptic soy agar Unknown  (Vidaillac, Leonard et al. 
2009) 
Tryptic soy agar 0.05  (Akins and Rybak 2000) 
Tryptic soy agar 0.05 2/86 hVISA isolates were 
found tolerant  
(Rybak, Leonard et al. 
2008) 
Unknown media 0.1 69.3% hVISA, 100% 
VISA and 14.7% clinical 
(Sader, Fritsche et al. 2006) 
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strains were found 
tolerant 
Muller-hinton + 5% 
sheep blood agar 
Unknown  (Torrico, Gimenez et al. 
2010) 
Blood agar 0.1 6.1% tolerance rate found 
in clinical strains 
(Traczewski, Katz et al. 
2009) 
Blood agar 0.1  (Wootton, MacGowan et al. 
2006) 
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10.7 Future studies 
This study has recognised there is a need to update the methodology used for tolerance testing, and there is 
a need for further standardisation among testing laboratories. Furthermore this study has established the 
utility of using the MDK90 of 6 h in a time-kill as a criteria for tolerance, which has demonstrated to be 
more robust when compared to existing criteria recommended by the CLSI.  
The results from this study also recommend the use of a vancomycin pre-exposure step prior to MBC 
testing. As tolerance is hypothesised to emerge during clinical therapy, a vancomycin pre-exposure step 
may resemble what happens to the organism in vivo and therefore may facilitate expression of the tolerance 
phenotype in a laboratory setting. 
Using recommendations from this thesis, inter-laboratory testing among institutions with similar 
hVISA/VISA culture libraries may address the variability seen in the reported rates of tolerance. Only via 
method standardisation and demonstrated inter-laboratory consistency will we be able to ascertain the 
prevalence of antibiotic tolerance and better understand its clinical relevance. 
 
10.8 Final remarks 
The results from this study contribute to the understanding of antimicrobial resistance for which widespread 
antibiotic use is a contributing factor. Antibiotic resistance is recognised as a significant global threat which 
is predicted to attribute to 10 million deaths worldwide by 2050, and will be associated with a global cost 
of 100 trillion USD (O'Neill 2015). Vancomycin was initially used to treat infections with penicillin-
resistant S. aureus before less-toxic drugs were introduced (Jones 2006). However due to the increasing 
prevalence of MRSA bacteraemia vancomycin has become most widely used antimicrobial agent for 
treatment. However, with the advent of reduced susceptibility and resistance to vancomycin seen in S. 
aureus strains, coupled by increasing reports of treatment failure seen in patients with MRSA bacteraemia, 
highlights why better understanding of the mechanisms of resistance in these strains is needed. However, 
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without a standardised approach to tolerance testing and clear established guidelines, this is unlikely to 
occur.   
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